Investigating the molecular pathology of Dupuytren’s disease by Pearce, Robert
The University of Notre Dame Australia 
ResearchOnline@ND 
Theses 
2018 
Investigating the molecular pathology of Dupuytren’s disease 
Robert Pearce 
The University of Notre Dame Australia 
Follow this and additional works at: https://researchonline.nd.edu.au/theses 
 Part of the Medicine and Health Sciences Commons 
 
COMMONWEALTH OF AUSTRALIA 
Copyright Regulations 1969 
 
WARNING 
The material in this communication may be subject to copyright under the Act. Any further copying or communication of this 
material by you may be the subject of copyright protection under the Act. 
Do not remove this notice. 
Publication Details 
Pearce, R. (2018). Investigating the molecular pathology of Dupuytren’s disease (Doctor of Philosophy (College of Medicine)). 
University of Notre Dame Australia. https://researchonline.nd.edu.au/theses/209 
This dissertation/thesis is brought to you by 
ResearchOnline@ND. It has been accepted for inclusion in 
Theses by an authorized administrator of ResearchOnline@ND. 
For more information, please contact 
researchonline@nd.edu.au. 
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  1 
  
  
Investigation of the Molecular Pathology of Dupuytren’s 
Disease 
 
Robert Pearce FRACS 
 
This thesis is presented for the degree of 
Doctor of Philosophy 
 
School of Medicine 
 
University of Notre Dame Australia 
(Fremantle) 
 
2018 
 
  
 
  
Contents   
 
Investigation of the Molecular Pathology of Dupuytren’s Disease ............................................................... 1 
ABSTRACT .................................................................................................................................................. 7 
ACKNOWLEDGEMENTS ........................................................................................................................ 10 
CHAPTER 1 .............................................................................................................................................. 11 
1.1 An overview of Dupuytren’s disease ................................................................................................ 11 
1.2 Current clinical management of Dupuytren’s disease ....................................................................... 13 
1.2.1 Prevention .................................................................................................................................. 13 
1.3 Surgery to treat Dupuytren’s disease ................................................................................................. 13 
1.3.1 Limited or partial fasciectomy.................................................................................................... 14 
1.3.2 Dermofasciectomy ..................................................................................................................... 14 
1.3.3 Z-Plasty repair ............................................................................................................................ 15 
1.3.4 Amputation ................................................................................................................................. 15 
1.3.5Percutaneous division of fibrous cords ........................................................................................ 16 
1.4 Non-surgical treatment of Dupuytren’s disease ................................................................................ 16 
1.4.1 Physical manipulation of Dupuytren’s contracture .................................................................... 16 
1.4.2 Irradiation ................................................................................................................................... 17 
1.4.3 Extracorporeal shockwave therapy ............................................................................................. 17 
1.5 Pharmacological treatments of Dupuytren’s disease ......................................................................... 17 
1.5.1 Intralesional steroid injection ..................................................................................................... 18 
1.5.2 Intralesional collagenase injection ............................................................................................. 18 
1.5.3 Intralesional gamma-interferon .................................................................................................. 18 
1.6 Summary ........................................................................................................................................... 19 
1.7 The Epidemiology of Dupuytren’s disease ....................................................................................... 20 
1.7.1 Epidemiological evidence for a genetic component to Dupuytren’s disease. ............................. 21 
1.8 The Molecular and cellular pathology of Dupuytren’s disease ......................................................... 22 
1.8.1 The role of myofibroblasts in Dupuytren’s disease .................................................................... 22 
1.8.2 The role of the immune system in Dupuytren’s disease ............................................................. 25 
1.8.3 A role for vascular and innervation changes in Dupuytren’s disease ......................................... 26 
1.9 Evidence for candidate susceptibility genes in Dupuytren’s disease ................................................ 27 
1.10 Summary ......................................................................................................................................... 31 
Hypothesis ................................................................................................................................................... 32 
Aims ............................................................................................................................................................ 32 
CHAPTER 2 .............................................................................................................................................. 33 
2.1 Introduction ....................................................................................................................................... 33 
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  3 
  
  
2.2 Methods ............................................................................................................................................. 35 
2.2.1 Ethics Approval .......................................................................................................................... 35 
2.2.2 Participants ................................................................................................................................. 35 
2.2.3 Saliva collection for genomic DNA isolation ............................................................................. 35 
2.2.4 DNA isolation protocol .............................................................................................................. 36 
2.2.5 DNA quantitation ....................................................................................................................... 36 
2.2.6 Whole exome sequencing (WES) ............................................................................................... 36 
2.2.7 Linkage analysis ......................................................................................................................... 38 
2.2.8 Variant confirmation and prioritization ...................................................................................... 38 
2.3 Results ............................................................................................................................................... 38 
2.3.1 Genes identified using the SOLiD platform ............................................................................... 38 
2.3.2 Genes identified using the Ion Proton sequencing platform ....................................................... 42 
2.3.4 Genes identified using the Illumina platform ............................................................................. 50 
2.3.5 Summary .................................................................................................................................... 50 
2.4 Discussion ......................................................................................................................................... 51 
2.4.1 Non-synonymous variants identified by WES in a family with Dupuytren’s disease ................ 51 
2.4.2 Genes involved in angiogenesis ................................................................................................. 54 
2.4.3 Genes with roles in inflammatory processes .............................................................................. 54 
2.4.4 Candidate genes with neural functions ....................................................................................... 55 
2.4.5 The absence of genes identified in previous studies ................................................................... 56 
2.4.6 The advantages of using WES to identify causative mutations .................................................. 57 
2.4.7 Limitations of using the WES approach ..................................................................................... 58 
2.5 Summary ........................................................................................................................................... 61 
CHAPTER 3 ............................................................................................................................................... 63 
3.1 Introduction ....................................................................................................................................... 63 
3.1.1 The Busselton Population Health Survey ................................................................................... 63 
3.2 Methods ............................................................................................................................................. 64 
3.2.1 Survey Responses ....................................................................................................................... 65 
3.2.2 Statistical power for association analysis ................................................................................... 65 
3.3 Results ............................................................................................................................................... 66 
3.4 Discussion ......................................................................................................................................... 72 
3.4.1 Findings in other linkage and genome wide association studies for Dupuytren’s disease ......... 72 
3.4.2 Possible role for genes in regions of interest from the Busselton GWAS study ........................ 73 
3.4.3 Comparison of results from the Busselton and family studies ................................................... 74 
3.4.5 Significance of environmental factors and genetic susceptibility .............................................. 76 
3.4.6 Limitations of this study ............................................................................................................. 78 
CHAPTER 4 ............................................................................................................................................... 80 
4.1 Introduction ....................................................................................................................................... 80 
4.2 Methods ............................................................................................................................................. 80 
4.2.1 Pathway analysis ........................................................................................................................ 81 
4.3 Results ............................................................................................................................................... 81 
4.4 Discussion ......................................................................................................................................... 87 
4.4.1 Identification of potential target genes ....................................................................................... 88 
4.4.2 Pathway analysis of combined genes of interest ........................................................................ 88 
4.4.3 Summary .................................................................................................................................... 89 
CHAPTER 5 ............................................................................................................................................... 90 
5.1 Introduction ....................................................................................................................................... 90 
5.2 Methods ............................................................................................................................................. 90 
5.2.2. Scar-in-a-jar model .................................................................................................................... 90 
5.2.2.1. Cell culture and isolation ........................................................................................................ 90 
5.2.2.2. Immunohistochemistry ........................................................................................................... 92 
5.2.2.3 Assessment of collagen quantitation ....................................................................................... 92 
5.2.2.4 Flourescence resonance energy transfer assay of procollagen ................................................ 93 
5.2.2.5. Statistical analysis .................................................................................................................. 94 
5.3 Results ............................................................................................................................................... 94 
Discussion ............................................................................................................................................... 97 
5.4.1 Summary .................................................................................................................................. 100 
CHAPTER  SIX ........................................................................................................................................ 101 
6.1 Summary ......................................................................................................................................... 101 
6.2 Identification of causative mutations in Dupuytren’s disease ......................................................... 103 
6.3 Identification of functional elements beyond the parameters of Whole Exome Sequencing – the 
ENCODE database ................................................................................................................................ 105 
6.5 Epigenetic influences in control of gene expression. ...................................................................... 106 
6.6 Whole Genome Sequencing (WGS) ................................................................................................ 107 
6.7 The identification of molecular changes in DD using disease derived cells. .................................. 107 
6.8 Possible non-fibroblast origin of Dupuytren’s  disease ................................................................... 109 
6.9 Neuronal activity/disruption and Dupuytren’s disease .................................................................... 110 
6.10 Angiogenesis and a role for vascular changes in Dupuytren’s disease ......................................... 112 
6.11 Fibroblasts, ECM changes and Dupuytren’s disease ..................................................................... 113 
6.12 Infection and Immune system involvement in DD ........................................................................ 114 
6.13 Future studies ................................................................................................................................ 116 
6.14 Summary ....................................................................................................................................... 117 
REFERENCES .......................................................................................................................................... 119 
 
 
  
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  5 
  
  
Figures 
Figure 1.1 Guillaume Dupuytren ................................................................................................................. 11 
Figure 1.2 Dupuytrens disease (DD (Palmar fibromatosis)) ........................................................................ 12 
Figure 1.3 Two stage model of myofibroblast differentiation ..................................................................... 24 
Figure 1.4 Mechanism of contracture in Dupuytren’s disease             25 
Figure 1.5 Signaling pathways with evidence of involvement in Dupuytren’s disease          29 
Figure 1.5 Summary of pathways and genes implicated in Dupuytren’s disease            31 
Figure 2.1: Deindentified family pedigree of family with autosomal dominant inheritance of Dupuytren's 
disease ......................................................................................................................................................... 35 
Figure 2.2: Sanger sequencing in family members for heterozygous non-synonymous variants in selected 
genes. .......................................................................................................................................................... 41 
Figure 2.3:  Linkage analysis of individual chromosomes                                                                                     46 
Figure 2.4: Sanger sequencing of candidate gene fragments in additional family members                        49 
Figure 2.5: Factors influencing fibroblast differentiation and function                                                             53 
Figure 4.1:Focal Adhesion Pathway genes implicated in DD                                                                               87 
Figure 5.3.1: Collagen quantitation in scar-in-a-jar model with normal skin and keloid scar fibroblasts   95 
Figure 5.3.2:Collagen quantitation in scar-in-a-jar model with fibroblasts from the wrist (control) and 
dupuytren cord (test).                                                                                                                                                96 
Figure 5.3.3:FRET assay of collagen I production by control and Dupytren fibroblasts                                 97 
 
  
Tables 
Table 2.1: List of candidate genes from WES analysis                                                                                39 
Table 1.2: Selected mutations for intial SNP analysis                                                                                            40 
Table 2.3: Sanger sequencing of putative causative variants in additional affected and non-affected family 
members                                                                                                                                                                        42 
Table 2.4: Variants identified in 4 family members by WES                                                                                 43 
Table 2.5: Linkage analysis to eliminate candidate genes                                                                                    45 
Table 2.6 Non-synonymous variants remaining after removal of those with a negative linkage score       47 
Table 2.7 In silico prediction of the likelihood of non-synonymous variants being deleterious to function  48 
Table 2.8: Additional genes identified that contained non-synonymous variants in family members 
sequenced using the Illumina WES platform.                                                                                                         50 
Table 2.1:Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton 
population using the dominant model                                                                                                                     67 
Table 3.2: Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton 
population using the additive model                                                                                                                        69 
Table 3.1:Non-synonymous polymorphisms identified in two related individuals with severe Dupuyren’s 
disease                                                                                                                                                                         82 
Table 4.2: Gene ontology enrichment analysis                                                                                                       85 
Table 4.3:KEGG pathway analysis                                                                                                                             86 
 
 
 
 
 
 
 
  
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  7 
  
  
ABSTRACT 
 
The eponymous progressive palmar fibromatosis described by Guillaume Dupuytren in 
1831 is a common and debilitating disease with limited treatment options and high rates 
of recurrence after intervention. Dupuytren’s disease has been generally accepted as 
predominantly affecting Northern European individuals; Dupuytren’s disease is 
sometimes referred to as “Vikings Disease” as an attribution to this ethnic origin. Its 
familial occurrence in all communities is suggestive of Mendelian inheritance as an 
autosomal dominant disease with incomplete penetrance. The genetic and molecular basis 
of Dupuytren’s disease (DD) has been the focus of many studies, with increasingly 
sophisticated approaches since the sequencing of the human genome in 2003. However, 
whilst the pathology of the progressive fibrosis is well understood, the etiology and 
molecular triggers of the disease remain unknown.  
This study has investigated the genetic basis of Dupuytren’s disease in families and the 
population of Western Australia. The study involved a tripartite investigation in patients 
from three different cohorts. The DNA of four DD affected people within a four-
generation family with autosomal dominant inheritance of DD was submitted for whole 
exome sequencing (WES) which initially identified 43 candidate genes with non-
synonymous heterozygous rare variants. Two candidate genes, EXOG and GORASP1, 
were in regions of positive linkage whilst the remainder were not excluded by linkage 
analysis. Sanger sequencing was focused on three candidate genes, EXOG, GORASP1 and 
COL6A5, but no variant segregated with Dupuytren’s disease in additional family 
members. No likely disease-causing variant was identified in all family members positive 
for the disease phenotype. 
 
A second cohort consisted of the Busselton study population, a study initiated in the 1960s 
and following the health outcomes of nearly 5000 people in Busselton WA. Using a survey 
48 unrelated individuals were identified as having had surgery for DD, whilst 409 people 
had evidence of early DD. DNA from the participants of the Busselton study was screened 
for SNPs using a GWAS chip approach and the data analysed to identify SNPs associated 
with DD. This study lacked sufficient power to identify statistically significant SNPs 
associated with the disease. A shortlist of variants was identified using an arbritrary p-
value cut-off. However, none of these SNPs were associated with genes in either the 
familial study or previous research. For the final genetic study DNA from another set of 
individuals with severe DD were subject to WES. The aim was to identify rare mutations 
in genes that may be associated with DD and that would promote the more aggressive 
phenotype in these individuals. Whilst no mutations in identical genes as previous studies 
were identified there was overlap in gene families and networks that suggests pathways 
that may be important in DD. Finally, fibroblasts isolated from some Dupuytren patients 
and control fibroblasts from the wrist were characterized using a modified ‘scar-in-a-jar’ 
protocol to investigate their collagen production. Interestingly, this model did not identify 
any differences between disease fibroblasts and control fibroblasts from the same patients. 
This may suggest that profibrotic signals in Dupuytren disease are external to the 
fibroblasts rather than autonomous. In addition it strongly suggests a need to develop more 
complex models to reproduce the disease state in vitro for further studies to understand 
the molecular basis of Dupuytren’s disease and  
The complexity of the known genetic susceptibility together with environmental factors, 
as well as the likely importance of non-coding and epigenetic factors continues to make 
identification of the genetic changes underpinning Dupuytren’s disease difficult. In 
addition limited in vitro and animal models for Dupuytren’s disease will continue to 
hamper therapeutic development and understanding. However, the studies here suggest 
common pathways may be implicated from the familial and population study approaches. 
Further work to identify the functional changes that underpin DD will be critical to the 
development of more effective treatment and prevention of the disease.  
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CHAPTER 1 
 
1.1 An overview of Dupuytren’s disease 
 
Dupuytren’s disease is the most common heritable disorder of connective tissue (Hu et 
al., 2005). Since his lectures to the staff at Hotel Dieu in Paris in 1831 (Dupuytren, 1834) 
the name of Baron Dupuytren has received universal acceptance to describe this 
progressive palmar fibromatosis, with or without contractures. Although he was unable to 
identify the true pathophysiology or aetiology of this condition, attributing its 
occupational cause to prolonged flexion of the digits in a coach-driver, Guillaume 
Dupuytren (Fig.1.1) has been credited with the 
earliest description of his eponymous disease. 
Dupuytren’s disease is characteristically a late-
onset fibromatosis affecting subcutaneous tissue of 
the palms and fingers (Fig. 1.2). It is relatively rare 
before the age of forty-five, with the mean age of 
onset in males of all races at fifty years (+/- five 
years) and fifty five years (+/- five years) in 
females (Pearce, 1991). 
 
 
In the pathogenesis of Dupuytren’s disease, 
subcutaneous fat is progressively replaced by 
relatively avascular fibrous tissue, which develops 
as nodules in the palm and extends distally into the 
digits as thickened cords. Tender palmar nodules and progressive shortening of cords 
across metacarpo-phalangeal and proximal interphalangeal joints, together with 
subsequent changes in other structures including collateral ligaments, cause functional 
disability (Fig. 1.2).  
Figure 1.1 Guillaume Dupuytren 
Progressive palmar fibromatosis was first 
described in 1831 by Baron Dupuytren 
 Figure 1 2 Dupuytrens disease (DD (Palmar fibromatosis)) 
DD is shown here affecting the palm in a 45 year old male with fibrous nodules in the 
palm extending as cords across the metacarpophalangeal and proximal interphalangeal 
joints causing flexion contractures 
 
Being a progressive condition that often presents in middle age with pain or digital 
contractures, Dupuytren’s disease is a common cause of disability interfering with manual 
dexterity in employment. In the majority of cases fibromatosis initially affects the palm 
and little finger, spreading in time across the palm radially, involving sequentially the ring, 
middle and index fingers. Less commonly there is a palpable band in the first web and 
isolated contracture across the metacarpo-phalangeal (MCP) joint of the thumb. A further 
unexplained occurrence is an isolated mid-palm cord extending into the middle finger with 
early contracture at the MCP joint, a finding statistically associated with diabetes mellitus 
(Ardic et al., 2003; Chammas et al., 1995; Eadington et al., 1989; Eadington et al., 1991; 
Early, 1962; Herzog, 1951). Both trigger finger and Dupuytren’s disease are common in 
the middle and ring fingers of the diabetic, sometimes referred to as the DDT syndrome 
(Burgess & Watson, 1987; McFarlane, 1991; Parker, 1979).   
 
Untreated digital contractures, particularly affecting both hands, can be very disabling as 
they progress in association with other co-morbidities of ageing. While collagenase 
injection into fibrous bands of Dupuytren’s tissue has met with limited success when used 
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in early stages of the disease, surgical intervention in established cases is currently the 
preferred treatment, with the best chance of functional recovery.  
 
The clinical indications for medical or surgical intervention are related to disabling palmar 
nodules, which can be painful and often interfere with everyday activities of life, or fibrous 
cords extending across the small joints of the hand causing digital contractures with 
limited extension of the metacarpo-phalangeal or proximal interphalangeal joints.  
 
In summary, Dupuytren’s disease is a late onset progressive fibromatosis, predominantly 
affecting males and with a disabling effect on the function of the hands. Whilst the clinical 
manifestations of disease progression are easily recognized and well understood, the 
molecular basis is not as clear.  
 
1.2 Current clinical management of Dupuytren’s disease 
 
1.2.1 Prevention  
The aetiology of Dupuytren’s disease is not well understood, particularly in relation to the 
part played by lifestyle and environmental factors. It is therefore not possible at this stage 
to advise preventive measures beyond notifying those identified as being at risk (through 
familial background) of the potentially harmful effects of smoking and alcohol. The 
possible application of knowledge gained from an understanding of the genetic basis for 
this disease to its prevention should be worth consideration. While epidemiological studies 
provide often biased and conflicting evidence in relation to occupation as a causative 
factor in Dupuytren’s disease there is no sound basis for considering employment in terms 
of prevention (Mikkelsen, 1978).  
 
1.3 Surgery to treat Dupuytren’s disease 
Since the identification of Dupuytren’s disease as a progressive, debilitating condition, 
surgery has been the primary treatment option. The majority of Dupuytren's disciples used 
multiple open wounds, operating in an era of unconfined suppuration and the anticipated 
drainage of laudable pus. Without the benefits of asepsis or antibiotics, this procedure was 
associated with significant mortality and morbidity. Another prominent French surgeon, 
Guillaume Goyrand, advocated the use of longitudinal incisions and open fasciotomies, 
while fifty years later William Adams appears to have pioneered the combination of post-
operative splinting with a closed subcutaneous fasciotomy technique in an attempt to 
reduce post-operative infection (Adams, 1885; Goyrand, 1833). 
 
Open operations did not become safe until the advent of antisepsis (following the work of 
Pasteur and Lister) and later developments of aseptic surgical technique. Fasciectomy, 
performed under general anaesthetic and tourniquet control, has subsequently supplanted 
fasciotomy as the operation of choice, although recent success without tourniquet and 
performed under local/regional anaesthetic will add a new dimension following the work 
of Lalonde of Toronto (Lalonde and Martin, 2014).  
 
1.3.1 Limited or partial fasciectomy 
Operating on only those areas of palpable fibrosis or contractures involving the small 
joints, dissection can be restricted to involved tissues that are safely excised through 
longitudinal incisions and under tourniquet. This approach has been widely favoured and 
recommended (Hamlin, 1952; Heuston, 1969; Skoog, 1963). Apart from some variations 
in operative and post-operative splinting, this operation is still the surgery of choice today 
(Hindocha, Stanley, Watson, & Bayat, 2006; Shih and Bayat, 2010). By avoiding or 
limiting dissection into normal tissue planes one avoids excessive scar tissue formation 
which inevitably transforms to Dupuytren’s tissue and results in recurrence (Bayat & 
McGrouther, 2006). 
 
1.3.2 Dermofasciectomy 
Sacrifice of skin is only contemplated when considered necessary to adequately remove 
underlying adherent Dupuytren’s tissue. It generally becomes an issue during the course 
of operation for recurrent disease. Extensive involvement of the palmar skin with 
adherence to underlying fibrosis sometimes necessitates excision of the skin and 
replacement with a full-thickness skin graft (dermofasciectomy). This technique was 
introduced by Maccallum in 1962 (Maccallum & Hueston, 1962) and has proved effective 
in reducing further recurrence (Hueston, 1984).                                     
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1.3.3 Z-Plasty repair  
The use of Z-plasties in repair of the skin incision has three main objectives: to assist in 
closure with adequate skin cover by rearrangement of flaps and lengthening the wound; 
to avoid a longitudinal scar across skin creases which may lead to scar contracture; and 
thirdly to realign the subcutaneous tissue and thereby reduce the chance of recurrence of 
contracture (Baker & Watson, 1980). 
 
Radical or total fasciectomy radical dissection of Dupuytren’s affected subcutaneous 
tissue across the palm is rarely performed. McFarlane has advocated an extensive removal 
of involved and potentially involved digital and palmar fascia (McFarlane, 1990), based 
on his description of three different types of cords found in relation to normal anatomical 
structures in the palm. Apart from being unnecessary in most cases, it implies removal of 
potentially normal tissue including the palmar aponeurosis. This surgery is also time-
consuming with the other disadvantage of a high recurrence rate (Clarkson, 1963). 
Selective dissection along affected bands of Dupuytren’s while preserving normal 
anatomy is much preferred. Luck and other authors who have reported extensive 
dissections have removed only involved fascia rather than perform a prophylactic 
fasciectomy (Luck, 1959; McIndoe & Beare, 1958; Iselin, 1955; McGregor, 1985; 
Hueston, 1961; McCash, 1964).   
 
 
1.3.4 Amputation 
Considered as a last resort following failed attempts at release of debilitating digital 
contractures, amputation must be thought of as an acceptable means of restoring a 
functional grip. The difficulty in straightening the proximal interphalangeal joint, 
particularly in the little finger, was appreciated by Dupuytren in 1831. Since then there 
have been numerous operations proposed in an effort to avoid amputation, including 
proximal interphalangeal joint arthrodesis or arthroplasty, division of flexor tendons, and 
wedge osteotomy of the proximal phalanx (Moberg, 1973), generally associated with post-
operative extension splinting (Ebskow et al., 2000; Larson and Jerosch-Herold, 2008). 
Amputation would be an appropriate option, however, if the complications of a useless 
finger are to be avoided and vascularized dorsal skin flaps can be utilized to replace 
involved skin on the adjacent palm (Tonkin, 1984).  
 
1.3.5Percutaneous division of fibrous cords 
This blind technique (to be distinguished from the open fasciotomy advocated by Astley 
Cooper in 1822) involves the use of a bevelled needle or fine scalpel to release a 
contracture, usually at metacarpo-phalangeal level, where a reasonably thin cord of 
Dupuytren’s can be palpated beneath the skin. Closed fasciotomy is almost confined to 
solitary contractures in the early stages of disease or in elderly patients who may not 
withstand more extensive surgery, as it can be performed under local anaesthetic. This 
minimally invasive procedure has good short-term results in mild or moderate 
contractures with a very low complication rate (Rowley et al., 1984; Foucher et al., 2003; 
Van Rijssen et al, 2006). While it may be considered a temporary measure (Van Rijssen 
& Werker, 2006), this approach is rarely considered appropriate in developing or 
progressive disease (Shaw et al., 1996). There are limited published data comparing 
medium-term outcomes of fasciectomy and closed percutaneous fasciotomy, but 
adherents to the latter procedure are aware of the complications involving skin tears and 
prolonged healing with frequent early recurrences. 
 
1.4 Non-surgical treatment of Dupuytren’s disease 
 
1.4.1 Physical manipulation of Dupuytren’s contracture 
Traumatic extension with rupture of fibrous cords responsible for digital contractures in 
Dupuytren’s disease was found to provide immediate though painful release of a flexion 
deformity (Hawkins, 1835).  When performed as an elective procedure under anaesthetic 
the excessive force required by passive extension is quite traumatic. Used in conjunction 
with percutaneous section of the cords there is increased likelihood of skin dehiscence 
with the problem of prolonged healing and no lasting benefit (Colville, 1983). 
 
A similar outcome results from sustained splinting with gradually increasing traction to 
release a flexion contracture. Where release of the contracture has apparently been 
successful there is almost universal evidence of recurrence within weeks of removal of 
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the traction apparatus (Shaw et al., 2007). Although it becomes an essential stage in the 
management of contractures by injection, physical manipulation per se is therefore no 
longer recommended to treat contractures due to Dupuytren’s disease (vide infra).  
 
1.4.2 Irradiation 
As a non-surgical intervention radiotherapy has been trialled in early-stage Dupuytren’s 
disease to reduce fibroblast activity (Keilholz et al., 1996). An estimated 87% of patients 
reported a subjective relief of symptoms while symptomatic cords and nodules were 
reduced in 75% (Seegenschmiedt, Olschewski, & Guntrum, 2001). Long term results in 
one study showed no progression of disease after thirteen years (Betz et al., 2010).  Apart 
from some minor late toxicity in the form of localized skin atrophy in 32% of cases, this 
would appear to be safe practice with no major complications. Significantly there has been 
no evidence of radiation-induced malignancy, contrary to early experience with exposure 
to X-rays. Whilst the results reported in the few studies on irradiation therapy have been 
positive, this treatment modality has not been widely adopted. The positive results are 
potentially due to the treatment of patients at a very early stage of localized disease 
development. Only a few patients present for medical advice at this early time, when 
surgery would not be considered as an option. 
 
1.4.3 Extracorporeal shockwave therapy 
Knobloch and others hypothesized in 2010 that focused extracorporeal shock wave 
therapy may be used as a non-invasive method of reducing palmar fibromatosis and 
progressive contractures in Dupuytren’s disease, on the basis of positive results obtained 
from a randomized-controlled trial in the management of Peyronie’s disease (Knobloch et 
al., 2011). The outcome of a similar trial with Dupuytren’s individuals suggests that this 
therapy may be useful in preventing or slowing the rate of contracture (without major 
complication), but long-term follow-up has not been reported. 
 
1.5 Pharmacological treatments of Dupuytren’s disease 
Other non-surgical or medical treatments have been attempted with variable degrees of 
success. Their rationale is based on the possible reversal or interruption of cellular activity 
of abnormal myofibroblasts in Dupuytren’s tissue and the removal or prevention of the 
excessive collagen deposition characteristic of this disease. Such treatments might 
therefore be expected to have some beneficial effect through direct or indirect limitation 
of collagen deposition, thereby limiting disease progression. They include:  injection of 
steroid, interferon or collagenase; ingestion of vitamin E, allopurinol or verapamil; Bassot 
(1965) and later Hueston advocated ‘enzymic fasciotomy’ as an alternative to surgery, but 
their results were not rewarding (Bassot, 1965; Hueston, 1974). 
 
1.5.1 Intralesional steroid injection 
The effect of steroids on Dupuytren’s disease has been investigated with reference to the 
role of programmed cell death; the progress of Dupuytren’s disease is seen as an 
imbalance between fibroblast activity and apoptosis. Both in vivo and with cultured 
Dupuytren’s cells, steroids were shown to increase the rate of apoptosis and to decrease 
rates of proliferation when compared with control fibroblasts (Meek et al., 2002).  
 
1.5.2 Intralesional collagenase injection 
Somewhat better results have followed various clinical trials using Clostridium 
histolyticum collagenase injections with release of limited contractures in the early stages 
of disease (Badalamente et al., 2002; Hurst et al., 2009). In America Clostridium 
histolyticum collagenase was approved by the FDA in February 2010 for use as an 
injectable treatment for Dupuytren’s disease (Shih & Bayat, 2010). Injection is followed 
by manipulation and attempted release of contracture after forty-eight hours.  Results to 
date have been variable and outcomes depend heavily upon case selection, clinical 
expertise and patient compliance. Reliable longer-term recurrence rates have yet to be 
determined. 
 
 
1.5.3 Intralesional gamma-interferon 
Pittet et al. (1994) tested the effect of Gamma-Interferon injected into Dupuytren’s tissue, 
and also hypertrophic scars (Pittet et al., 1994).  Gamma-interferon has been shown to 
decrease fibroblast replication, alpha smooth muscle actin expression and collagen 
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production. Some decrease in lesion size has been observed in hypertrophic burn scars 
and Dupuytren’s nodules with no significant release of contractures. 
 
Although there is some advocacy in recent years for pharmacological and other minimally 
invasive treatments as temporary or palliative control of limited fibrosis in selected cases 
of Dupuytren’s disease, none of these methods has been adopted universally as alternative 
treatment on a routine basis. 
 
1.6 Summary 
In summary, the primary treatment modality for Dupuytren’s disease is currently surgical 
intervention, with removal of the cord tissue, release of debilitating contractures and 
salvage of normal surrounding tissue. This has been effective also in slowing the 
progression of Dupuytren’s disease in many cases, but the progressive nature of the 
disease can lead to recurrence and continued disability. There are also potential risks 
inherent in the surgical procedures, most notably associated neurovascular trauma that can 
be avoided by careful dissection, and scar contractures that are often painful. Sympathetic 
dystrophy as a complication of hand surgery is disabling, inexplicable, resistant to 
treatment and fortunately rare.  
 
Other conservative treatment options, predominantly pharmacological, have been 
developed and are subject to clinical controlled trials, long-term follow-up and 
assessment. These have generally shown limited efficacy, at least in part due to an 
incomplete understanding of the molecular pathology. In a recent review of surgical and 
medical advances in the management of Dupuytren’s disease (Mafi et al., 2012) the 
authors have emphasized the importance of genetic studies in elucidating the cause of the 
disease with the prospect of preventing its progression.   
 
In line with current understanding of the clinical progression and treatment of Dupuytren’s 
disease therefore, there is reason to believe that further elucidation of its molecular 
pathology and aetiology might result in new treatments and potentially improved 
outcomes.  
 1.7 The Epidemiology of Dupuytren’s disease 
 
Dupuytren’s disease is generally uncommon before the age of forty-five.  Although the 
age at which palmar fibromatosis in adults first becomes apparent can be difficult to 
establish, the average age of onset is generally accepted as being 50+/- 5 years for males 
and 55+/- 5 years for females (Hindocha et al., 2006). Beyond the age of fifty years the 
prevalence of Dupuytren’s disease in any population study increases with age until about 
80 years, when it tends to plateau (Early, 1962; Khan et al., 2004). There is a definite 
gender bias, generally accepted as approximately M:F = 6:1 in the 60-70 year age group, 
with variable figures beyond this age, but the observed convergence of male and female 
incidence after eighty years could be due to a combination of population changes, 
hormonal imbalance and the variable effects of age-related comorbidities and lifestyle 
factors. 
 
Ageing itself could be instrumental in progressing the fibromatosis as with other 
neoplasms, possibly related to diminishing immune response and nuclear/chromosomal 
fragility. Specific neurovascular changes have not been identified in Dupuytren’s tissue, 
but could become secondary factors in the activity of fibroblasts as relatively avascular 
collagen deposits accumulate.  With an ageing population raised triglyceride levels, 
hypercholesterolaemia and hypertension as well as Dupuytren’s disease become more 
prevalent - to date there is nothing to suggest that there is any common causal relationship. 
 
The possible role of associated conditions in the aetiology of Dupuytren’s palmar 
fibromatosis has received much attention in world literature (P. Burge, Hoy, Regan, & 
Milne, 1997; P. D. Burge, 2004; Gordon, 1954; Hindocha, Stanley, et al., 2006; 
Mackenney, 1983; Carson and Clarke, 1993; Loos et al., 2007)  Associated conditions 
referred to include:  diabetes mellitus, osteoarthritis, hypercholesterolaemia, hypertension, 
and gout, all of which are closely related to ageing.   
 
The relevance of some of these factors to the aetiology of Dupuytren’s, including alcohol 
abuse, epilepsy, hypercholesterolaemia, hepatic cirrhosis, smoking and diabetes mellitus, 
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has been questioned (Carson and Clarke, 1993; Schiavon et al., 2004; Loos et al., 2007) 
The association of Dupuytren’s with epilepsy is uncertain (and denied by some authors on 
a statistical basis; Mackenney, 1983) but the highest prevalence rate was reported in a 
study group of adult epileptic patients in the United Kingdom (56%, 1976). However there 
is a huge discrepancy with other similar studies (eg Germany, 20% and France, 9%; 
Hindocha, McGrowther and Bayat, 2009). Whilst there are a number of links associating 
the presence of Dupuytren’s disease with other conditions, to date no causative links 
between Dupuytren’s disease and other pathologies has been established, and in fact 
ageing may be the common link between the diseases rather than any specific molecular 
pathology.  
 
1.7.1 Epidemiological evidence for a genetic component to Dupuytren’s disease. 
Dupuytren’s disease is most common in Caucasian adults of Northern European ancestry 
(Bayat and McGrouther, 2006). Various surveys have been published to report the 
occurrence of Dupuytren’s disease among other ethnic communities; African Americans 
(Gonzalez et al., 1998; Mitra & Goldstein, 1994; Sladicka et al., 1996) Chinese-oriental 
(Egawa et al., 1990) Japanese (Abe et al., 2007); African (Makhlouf et al., 1987; Mennen, 
1986; Muguti & Appelt, 1993; Richard-Kadio et al, 1997); Icelandic (Gudmundsson et 
al., 2000); Chinese (Liu & Chen, 1991); Thai (Vathana et al., 1990) and Indian (Srivastava 
et al., 1989) populations as well as Eastern European and Mediterranean cohorts (Zerajic 
& Finsen, 2004), with varying rates of incidence in these different populations. The ethnic 
influence becomes more apparent when migrant populations from Poland or Scandinavia 
examined in America are found to show similar rates of disease as found in their countries 
of origin (Soboeiro, 2000), suggesting the importance of genetics rather than environment 
in the incidence of Dupuytren’s disease. Nevertheless, environment is also likely to play 
a role, as evidenced by the study of Finsen and colleagues (2002) who studied two ethnic 
groups in northern Norway. Without identifying specific factors that might influence the 
occurrence of Dupuytren’s, the findings showed that family members were more likely to 
develop Dupuytren’s disease if they lived in the same geographic area as their affected 
relatives. 
 
Despite the many studies linking Dupuytren’s disease to other environmental factors, 
family history is undoubtedly one of the strongest predictors of susceptibility. This clearly 
demonstrates that there is a substantial genetic influence on the development of 
Dupuytren’s disease. The inheritance pattern of Dupuytren’s disease was studied by 
Burge, who reported: 
“Characterization of autosomal dominant inheritance in this condition is reinforced by the 
occurrence of affected individuals, both male and female, in consecutive generations, with 
evidence of transmission female to male, and variations in degrees of penetrance,” (Burge, 
1999). The more recent ‘Rejkavik Study’ reported by Gudmundssen and colleagues that 
recorded a large Icelandic family pedigree with affecteds in three generations, reached 
similar conclusions (Gudmundsson et al., 2000). Therefore strong evidence exists for a 
significant genetic component to the occurrence of Dupuytren’s disease. Understanding 
the key genes that underpin this link will be important to understand the disease and 
ultimately to develop better treatments. 
 
1.8 The Molecular and cellular pathology of Dupuytren’s disease 
Dupuytren’s disease involves progressive, increasing deposition of stable collagen and 
extracellular matrix proteins, with subsequent contracture of the matrix through the 
activity of fibroblast subpopulations. Whether the increased density of the matrix is caused 
by excessive production or reduced degradation is as yet unclear, and the molecular 
signals that trigger this process unknown. There is some evidence that the immune system 
is important in Dupuytren’s disease, whilst other studies suggest that innervation and 
neuroinflammatory mediators may be involved. Nevertheless, whilst the molecular and 
cellular triggers remain difficult to elucidate, the progressive increase in extracellular 
matrix and subsequent contraction clearly involves myofibroblasts (Gabbiani & Majno, 
1972). This section will review the evidence and possible roles of different cells and 
systems in the pathology of Dupuytren’s disease. 
 
1.8.1 The role of myofibroblasts in Dupuytren’s disease 
The cellular structure and biology of the myofibroblast were elucidated by Gabbiani, 
Majno and Ryan (Gabbiani & Majno, 1972; Gabbiani et al., 1973), and others  (Tomasek 
and Haaksma, 1991; Tomasek et al., 1999; Skalli and colleagues, 1989). The contractile 
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mechanisms of the myofibroblasts in Dupuytren’s disease were first investigated by 
Badalamente and colleagues in relation to the pathogenesis of contractures in this disease 
(Badalamente et al., 1983). Factors involved in the differentiation of these cells at a 
molecular level and the activation of their innate contractility in the progression of 
Dupuytren’s disease have been further studied by Verjee et al. (2013).  
Connective tissue contracture as occurs in Dupuytren’s pathology is “a sustained, low-
energy shortening process which involves matrix-dispersed cells and is dominated by 
extracellular events such as matrix remodeling” (Tomasek, 2002; Glimcher & Peabody, 
1990). Histological examination of Dupuytren’s tissue readily confirms the relative 
hypocellularity in a dense matrix of collagen in established disease. Multinucleated cells 
have been observed in all clinical stages of progressive fibromatosis. Whether due to 
fibroblast fusion or nuclear division without cytokinesis, the fact that multinucleated 
fibroblasts can originate via different mechanisms may influence their behaviour in 
various conditions including in vitro culture assays and in certain fibroblastic pathologies 
such as foreign body response, fibrosis, cancer and aged tissue (Holt and Grainger, 2011). 
 
In Dupuytren’s disease, as in normal wound healing, collagen type I is largely replaced 
by type III collagen which is known to be present in remodeling tissues, or in normal 
tissues that are subject to mechanical stress (Gabbiani et al., 1976). The remodeling, which 
is an essential element in the progressive shortening process of contracture formation, 
involves removal of matrix molecules and is largely mediated by metalloproteinases 
which allow slippage and re-apposition of adjacent fibrils. 
 
It is thought that the contractile force generated by myofibroblasts translates into collagen 
network shortening through fibronexus adhesion complexes that are linked to intracellular 
stress fibres. These factors (stress fibres and adhesion complexes with the extracellular 
matrix) are distinctive features for differentiated myofibroblasts. These cells generate 
sustained contractile force, which is generated by contractile stress fibres composed of 
bundles of actin microfilaments with associated non-muscle myosin and other actin-
binding proteins. The production of matrix and subsequent response to the matrix to 
trigger contraction is critical to the pathology of Dupuytren’s disease.  
 Under mechanical stress, fibroblasts can undergo a two-stage differentiation process 
(Figure. 1.3). The fibroblasts first differentiate into proto-myofibroblasts, which form 
cytoplasmic actin-containing stress fibres that terminate in fibronexus adhesion 
complexes (Tomasek et al, 1991; 2002). Proto-myofibroblasts also express and organize 
cellular fibronectin at the cell surface and are capable of generating contractile force. The 
combination of transforming growth factor 1 (TGF-1) with cellular fibronectin and 
continued mechanical tension facilitates the final stage in formation of the differentiated 
myofibroblast (Fig. 1.3). Therefore it is likely that during the initiation and progression of 
Dupuytren’s disease the initial mechanical stress triggers fibroblast differentiation and 
production of TGF-1, leading to increased mechanical stress and subsequently a negative 
cycle of increased matrix production, fibroblast differentiation to myofibroblasts and 
contraction This cycle of degradation and production of the matrix leads to shortening and 
contracture (Fig. 1.4). 
.  
Figure 1.3 Two stage model of myofibroblast differentiation Mechanical tension and the 
expression of specific growth factors lead to fibroblast differentiation into myofibroblasts. Increasing myofibroblasts 
increases tension and propagates the transition (from Tomasek et al., 2002). 
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Fig. 1.4 Mechanism of contracture in Dupuytren’s disease 
 (as described in Tomasek et al, from Ketchum LD, 2014) 
 
1.8.2 The role of the immune system in Dupuytren’s disease 
The possibility of Dupuytren’s being a T-cell mediated autoimmune condition has been 
proposed and the finding of increased numbers of DR+ T-cells in the circulation may 
support an immunological mechanism in its pathogenesis (Gudmundsson et al 1998).  The 
role of the highly polymorphic human leucocyte antigen (HLA) has also been 
investigated, particularly in relation to genetic susceptibility to develop fibromatosis 
(Gudmundsson et al., 1998). A significant association between affected patients and HLA-
DR3 and autoantibodies to proteins contained in the extra-cellular matrix (elastin and 
collagen types 1-4) suggests a correlation with the process of remodelling during the 
course of fibrosis (Neumuller et al., 1994). 
 
McCarty and colleagues have explored the immunogenetic component of this condition 
and published a review of previous studies (McCarty et al., 2010). These authors 
concluded: “There is a clear association with specific HLA alleles and predilection or 
protection to Dupuytren’s disease. In particular, the class II HLA-DR locus is the most 
promising region for a biomarker of Dupuytren’s disease.  The ability to accurately 
perform an assessment of an individual’s potential immunogenetic susceptibility to 
Dupuytren’s disease may potentially lead to a more personalized approach to their 
diagnostic, therapeutic and prognostic management in the future”. 
 
More recently, a characterization of the cells present in Dupuytren’s tissue using 
immunohistochemistry found signiﬁcant numbers of immune cells, including classically 
activated macrophages. High levels of proinﬂammatory cytokines (eg tumour necrosis 
factor, TNF) were also detected in tissue from Dupuytren’s patients (Verjee et al., 2013). 
Verjee et al. also demonstrated a link between TNFa and the differentiation of fibroblasts 
into myofibroblasts,  particularly in cells isolated from Dupuytren’s tissue. This suggests 
that the microenvironment may influence fibroblast phenotype, and that these changes 
could be mediated by the immune system. These studies indicate that the immune system 
may play an important role in the etiology and pathology of Dupuytren’s disease. 
However, whilst inflammation has a strong link to fibrosis during wound healing, the 
mechanistic link between immune activation and Dupuytren’s disease is not clear. Many 
of these observations may be indicative of immune responses rather than drivers of the 
disease, and the potential importance of other mechanisms cannot be overlooked.  
 
1.8.3 A role for vascular and innervation changes in Dupuytren’s disease                       
The search for control factors that may influence the growth and activity of myofiboblasts 
and the production of collagen in the extracellular matrix has provided an important focus 
for extensive laboratory investigations over the closing decades of the 20th century. 
Morphological evidence consistent with localized microvascular ischaemia (Hussl, 1979; 
Maccallum & Hueston, 1962; Murrell & Hueston, 1990) in Dupuytren’s tissue has been 
observed. 
 
Murrell and colleagues (Murrell et al., 1987; Murrell et al., 1989) also showed that 
superoxide free radicals and hydroxyl radicals, which are produced during the metabolism 
of adenosine triphosphate to xanthine and uric acid, are released in Dupuytren’s tissue. “A 
six-fold increase in the concentration of hypoxanthine in Dupuytren’s tissue and in the 
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activity of xanthine oxidase have been demonstrated and these have a stimulatory effect 
on the proliferation of fibroblasts” (Thurston, 2003). These findings are significant in light 
of the strong association between Dupuytren’s disease and gout, diabetes mellitus and 
smoking, with their inherent metabolic and peripheral vascular changes known to be 
associated with these diseases. In particular the link between Type II diabetes mellitus and 
the incidence of Dupuytren’s disease suggests the peripheral vascular changes may be 
important in this disease. Other studies have clearly shown that vascular changes can 
influence fibroblast phenotype (Misra et al., 2010; Watson et al., 2014), with hypoxia 
leading to a more myofibroblast phenotype and likely to be important in fibrosis in at least 
some tissue types. However, to date the evidence in Dupuyren’s disease is associative 
rather than causative, and no clear studies have demonstrated a link between changes in 
vascular function and Dupuytren’s pathology. 
 
1.9 Evidence for candidate susceptibility genes in Dupuytren’s disease 
Identification of proteins/genes important in Dupuytren’s disease has largely been focused 
on two approaches. One is the identification of genes associated with Dupuytren’s disease 
through standard genetic approaches. The other is the proteomic or transcriptomic analysis 
of disease tissue compared to control tissue (commonly in the same patients). Both these 
approaches provide an opportunity for insight into the molecular pathology of the disease, 
but to date no conclusive evidence for the mechanism of induction of Dupuytren’s disease 
or the specific mutations involved has been generated. 
 
As early as 1984 Iwasaki and colleagues studied the histopathology of Dupuytren’s 
disease and concluded that growth factors induce proliferation of genetically abnormal 
myofibroblasts (Iwasaki et al.,1984). Subsequently, the studies of Baird (Baird et al., 
1993) among others have implicated transforming growth factor  (TGF) cytokines and 
receptors in the regulation of cell proliferation, migration and differentiation, and 
therefore as a major factor in the pathogenesis of Dupuytren’s disease (Alioto et al., 1994; 
Badalamente et al., 1996; Berndt et al., 1995; Kloen et al., 1995; Tomasek et al., 1999).  
These receptors were therefore seen to represent candidate susceptibility genes for 
Dupuytren’s disease and were submitted to further investigation (Bayat et al., 2003). A 
statistically significant difference in genotype frequency distributions between cases and 
controls for TGFR1 polymorphisms in the recessive model was observed in these studies. 
The genotype or allele frequency distributions for other TGF receptors were not 
significantly different between controls and Dupuytren’s patients. Their conclusion 
therefore, was that Dupuytren’s appears to be a complex oligogenic condition in which 
the TGF signaling system plays an essential role. From a more recent study by Zhang et 
al. a gene expression analysis of Dupuytren’s cord tissue, over twenty unique genes 
(including several previously reported) were identified and found to be significantly 
upregulated, ie expressed uniformly at much higher levels than in the controls (Zhang et 
al., 2008). Shih et al. (2009) performed similar genetic studies for identification of 
biomarkers in Dupuytren’s tissue by comparative analysis with non-specific fibroblasts 
(Shih et al., 2009) while differentially expressed genes were identified in fibroblasts from 
Dupuytren’s tissue by Satish and colleagues (Satish et al., 2011). While increased 
expression of these genes suggests that they play a role in the disease process it is not clear 
if this is promoting the disease or a response to ameliorate the fibrosis.    
 
Genetic approaches have led to the idenfication of several chromosomal regions thought 
to be associated with Dupuytren’s disease. One of the earlier genetic studies reported 
mapping of an autosomal dominant gene for Dupuytren’s to chromosome 16q in a 
Swedish family (Hu et al., 2005; Shih et al., 2011). However, this has not been supported 
by more recent investigations. 
 
Shih et al. also noted the potential role for Matrix Metalloproteases (MMPs) and the Wnt 
signalling pathway in Dupuytren’s disease (Shih et al., 2012). This is supported by the 
findings of a large genome-wide association study (GWAS) into the genes associated with 
Dupuytren’s disease (Dolmans et al., 2011; Ojwang et al., 2010). This study, reported in 
the New England Journal of Medicine, involved a GWAS of 960 Dutch persons with 
Dupuytren’s phenotype and 3117 controls, to test for association between the disease and 
genetic markers. Nine different loci involved in genetic susceptibility to Dupuytren’s 
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disease were identified, six of them found to harbour genes encoding proteins involved in 
the Wnt-signalling pathway. This finding strongly suggests that aberrations in this 
pathway are key to the process of fibromatosis in this disease. However, whilst this data 
is convincing again the functional data linking the genes identified with Dpuytren’s 
disease remains lacking, and whilst Wnt signalling is known to be important in fibrosis 
(Piersma, 2015), again there is limited data directly linking specific genes within this 
pathway or mutations in specific genes to Dupuytren’s disease. Other signalling pathways 
such as the ‘sonic hedgehog pathway’ and the ‘TGF signalling pathway’ are also known 
to involve genes that are linked to Dupuytren’s development and progression of fibrosis 
(Fig.1.5), and are thought to converge and result in fibroblast to myofibroblast transition, 
thus promoting the progression of Dupuytren’s disease (Fig.1.5).  
 
Figure 1.5 Signaling pathways with evidence of involvement in Dupuytren’s disease 
WNT, TGF and Mechanotransduction pathways have all been implicated in the pathogenesis of Dupuytren’s 
disease through genetic, molecular and cellular studies (taken from Musumeci M et al, 2015) 
Unravelling the signalling pathways promoting fibrosis in Dupuytren’s disease has 
revealed TNF (tumour necrosis factor) as the only pro-inflammatory protein mediator 
(cytokine) to selectively convert normal fibroblasts from the palm of patients with 
Dupuytren’s disease into myofibroblasts via the Wnt signalling pathway (Verjee et al., 
2013). The same authors reported reversal of the myofibroblast phenotype by blockade of 
TNF (by reducing expression of alpha smooth muscle actin and inhibiting contractile 
activity of myofibroblasts) and concluded that TNF inhibition may be considered a 
therapeutic target in the prevention of progression or recurrence of Dupuytren’s disease. 
 
From analysis comparing fibroblasts with disease-specific phenotype from tissue biopsies 
to control cells Shih et al. found 25 candidate genes, further short-listed to six genes via 
functional annotation, and subsequently identified ADAM12, POSTN and TNC as 
potential biomarkers for Dupuytren’s disease. The review by same authors showed two 
genes highlighted by both gene-expression profiling and whole genome association 
studies – MAFB and PRKX (a sex-linked protein kinase), whilst MAFB has also been 
associated with Dupuytren’s disease in another study (Lee et al., 2006).  
 
Tissue studies for gene expression in fibroblasts have also been used to demonstrate 
transcription profile differences between Dupuytren’s disease and normal control 
fibroblasts (Forrester, 2013). Results indicate that in Dupuytren’s disease there is an 
excess of collagen and other ECM that is not controlled due to a reduction in matrix 
metalloproteinases and other matrix remodelling proteins (Shih, 2009; Forrester, 2013). 
A reduction in the fibrotic control protein, follistatin, may also contribute to development 
of Dupuytren’s disease (Forrester, 2013). In summary, there have been a number of studies 
investigating the molecular pathology and genetics of Dupuytren’s disease. Whilst many 
of the studies have small sample numbers and limited power, the same consistent themes 
have emerged over time. A role for Wnt signaling has been supported in many genetic and 
expression-based studies, whilst the TGF pathway has also been heavily implicated, as 
in many other fibrotic diseases (Shih, 2012, Fig. 1.5)). Nevertheless, there remains a gap 
in the knowledge to demonstrate the molecular pathogenesis of Dupuytren’s disease. 
Genetic approaches remain one of the most likely options to progress our understanding 
of this disease. 
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Fig. 1.6 Summary of pathways and genes implicated in Dupuytren’s disease  
(Taken from genetic and molecular/cellular biology studies (from Shih, Watson and Bayat, 2012)) 
 
1.10 Summary 
Despite many years of investigation into the molecular and genetic factors that may be 
important in Dupuytren’s pathology, no clear mechanism has yet been described to 
explain the triggers that lead to Dupuytren’s fibrosis. The use of disease tissue is limited 
by the difficulty of identifying responsive and causative changes, whilst genetic studies to 
date remain inconclusive without the necessary additional functional validation. Therefore 
there is a need for further investigation into the possible causes of Dupuytren’s disease at 
the molecular and genetic level. Understanding the triggers and key pathways that are 
important in Dupuytren’s disease will be critical to change the treatment paradigm from 
one of symptom limitation to disease prevention. In this thesis, different genetic strategies 
have been used to identify genes that may be important in the pathogenesis of Dupuytren’s 
disease in the Western Australian population. The clear genetic basis for the disease in 
specific families provides an opportunity to identify causative rather than responsive 
genes involved in the pathology. Therefore the first study was to investigate potential 
causative mutations in an individual Western Australian family with inherited 
Dupuytren’s disease. 
 
Hypothesis 
 
That heritable Dupuytren’s disease is caused by a non-synonymous mutation leading to 
defective protein function and the onset of palmar fibromatosis. 
Aims 
 
1. To use whole exome sequencing (WES) of a Western Australian family with 
autosomal dominant inheritance of Dupuytren’s disease to identify putative causative 
mutations. 
 
2. To investigate the presence of the putative mutations in a wider population-based 
cohort of people with Dupuytren’s disease. 
 
3. To evaluate the putative mutations from Aims 1 and 2 in unrelated individuals 
with Dupuytren’s disease.  
 
4. To investigate the functional consequences of the putative mutations identified in 
Aims 1-3 on fibroblast phenotype and pathobiology with relation to Dupuytren’s 
disease. 
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CHAPTER 2 
 
Aim 1.To use whole exome sequencing (WES) of a Western Australian family with 
autosomal dominant inheritance of Dupuytren’s disease to identify putative causative 
mutations 
. 
2.1 Introduction 
 
The genetic defects underlying inherited traits have traditionally been investigated 
using linkage analysis. This technique involved the use of microsatellite markers 
located throughout the genome and found in linkage disequilibrium as the basis for 
identifying regions inherited in affected individuals within a family and not in those 
that were unaffected, ‘linking’ the causative defect to the regions identified 
(Chistiakov et al., 2006). In the case of Dupuytren’s disease, a previous linkage study 
has been performed in a Swedish population and suggested an important region was 
located on Chromosome 16. The single region identified was approximately 30cM in 
size, bound by markers D16S3131 and D16S514 with a LOD score of >1.5. The LOD 
score was improved to LOD 3.18 when two affected cousins were genotyped with 
additional microsatellite markers, supporting linkage to the region on chromosome 16 
(Hu et al., 2005). However, traditional linkage studies such as this have been limited 
by low resolution and an inability to progress to identification of specific genes of 
interest.  
 
More recent approaches using single nucleotide polymorphisms (SNPs) as markers 
throughout the genome (of which >2 million have been identified) to identify regions 
of interest have provided much higher resolution and greater ability to identify gene 
mutations involved in disease (Stranger et al., 2011). These studies, however, are still 
not optimal and significant challenges in identifying causative mutations and 
functional data nevertheless remain (Edwards et al., 2013).  
 
One large population study reported in the New England Journal of Medicine 
identified nine possible Dupuytren’s disease-associated loci on three different 
chromosomes (7, 19 and 22), in a GWAS involving 960 Dupuytren’s patients and 
over 3000 controls (Dolmans et al., 2011). Six of the nine associated loci were found 
to harbour genes encoding proteins involved in the Wnt-signaling pathway. However 
no functional evidence supporting a role for the Wnt-signaling pathway or identified 
genes was provided, and the presence of multiple other genes residing in the identified 
regions leaves doubt as to the relative importance of Wnt-signaling to Dupuytren’s 
pathology.  
 
An alternative approach that has recently been used in studies of inherited disease 
within families is the use of whole exome sequencing (WES) (Rabbani et al., 2014). 
This approach involves sequencing the part of the genome encoding for proteins to 
identify varaints that are likely to affect protein function and therefore underlie 
disease.  This approach is limited in that only functional variants (rather than those 
affecting expression levels, for example within promoter regions) can be identified. 
However, many disease-causing variants (mutations) have been identified using this 
approach, which has the significant advantage over GWAS methodology in actually 
identifying variants in specific genes that can be further characterized (Bao et al., 
2014; Rabbani et al., 2014). 
 
Here, we have used WES in four members of a Western Australian family with 
autosomal dominant Dupuytren’s disease. The four members of the family initially 
sequenced were all affected individuals with Dupuytren’s disease. Heterozygous, 
non-synonymous variants present in all 4 individuals were identified. These variants 
were subsequently investigated using PCR in other affected and unaffected members 
of the family to determine those most likely to underlie the Dupuytren’s pathology.  
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2.2 Methods 
 
2.2.1 Ethics Approval  
All human studies complied with the National Health and Medical Research Council 
statement on ethical conduct of human studies and were approved by the Notre Dame 
Human Research Ethics Committee.  All participants received a patient information sheet 
and had any questions answered by Dr Pearce prior to providing informed consent 
(Appendix 1). 
 
2.2.2 Participants 
Members of a family related to a previous patient of Dr Pearce who had been identified 
as having Dupuytren’s disease were identified and examined for phenotypic evidence of 
Dupuytren’s disease by Dr Pearce. Related siblings, children of a second generation and 
spouses by marriage were included (Fig. 2.1).  All members were interviewed and 
examined by Dr Pearce for the presence of Dupuytren’s disease. DNA was collected from 
all consenting participants.  
 
2.2.3 Saliva collection for genomic DNA isolation 
Sputum samples were collected from fifteen members who were clinically diagnosed with 
Dupuytren’s disease and from eight non-affected family members (Figure. 2.1) using 
Oragene saliva collection kits (DNAGenotek) and stored at 4 oC until DNA was isolated. 
 
Figure 2.1: Deindentified family pedigree of family with autosomal dominant inheritance of Dupuytren's disease  
Affected family members are highlighted with red, unaffected samples are completely white. Deceased 
family members have a strikethrough symbol as per standard representation. 
 DNA samples were collected from 23 members of the family including affected and 
non-affected individuals. Red indicates affected individual with clinical diagnosis of 
DD. 
 
2.2.4 DNA isolation protocol 
DNA was isolated using the manual purification protocol (as per manufacturer’s 
instructions). This procedure produced a median yield of 110µg of DNA from 2ml of 
saliva collected in a 4ml Oragene saliva collection tube. 
 
2.2.5 DNA quantitation  
DNA samples were quantified using a Nanodrop spectrophotometer (ND-1000, 
Thermoscientific Instruments). For each sample a 1l aliquot was removed and DNA 
concentration calculated. 
 
2.2.6 Whole exome sequencing (WES) 
 
2.2.6.1 SOLiD Platform 
WES was initially performed for 2 affected and one unaffected family member (D3, D12, 
D18, Fig. 2.1) at the Lotterywest State Biomedical Facility Genomics (LSBFG) node 
(Perth, Western Australia) in a previously described method (Ravenscroft et al., 2013). 
Sonication was used to fragment 3μg of DNA from each individual; DNA was fragmented 
by and ligated to sequencing adaptors (SOLiD). Exomic sequences were enriched from 
the resulting libraries (SeqCap EZ Human Exome Library v2.0 exome capture system; 
Nimblegen, Roche Diagnostics). Sequencing was performed using a 5500XL SOLiDTM 
system (Applied Biosystems). After alignment the exomes were covered to >20-fold for 
at least 80% of the targeted sequence.  
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LifeScopeTM 2.5 (Life Technologies) was used to call variants against the GRCh37 
human reference genome, which were subsequently filtered using ANNOVAR (Wang 
et al., 2010). Filtering included exclusion of variants in the 1000 Genomes database 
(Clarke et al., 2012) if variants had a minor allele frequency greater than 1%, and 
removal of SNPs in the dbSNP135 common database. 
2.2.6.2 Ion Proton 
A second whole exome sequencing approach was next undertaken using the Ion ProtonTM 
platform (Ampliseq chemistry, Life Technologies) and was also performed at the LSBFG, 
as previously described  (Todd et al., 2015). Four affected family members (D4, D6, D8, 
D31) were processed with this technique. Twelve PCR pools were used to create libraries 
from 100ng of DNA from each individual. Libraries were purified and amplified for two 
rounds using AMPure beads (Beckman Coulter) and Platinum® High-Fidelity Taq 
Polymerase respectively. An Ion Proton™ Template 200 v3 kit was used to attach Ion 
Sphere™ Particles to the libraries (diluted to 18-26pM). Sequencing was performed using 
a P1 sequencing chip with an Ion Proton sequencer™. 
 
All exomes were covered to >20-fold for >90% of the targeted sequence. Sequence 
variants were analysed using in-house scripts, again based on ANNOVAR software. 
Variants were excluded if they appeared at a frequency of >0.5% in the Exome 
Sequencing Project, 1000 Genomes or ExAC Browser databases, and if they appeared in 
the dbSNP137 common database. Pathogenicity predictions were made using the online 
prediction software programs SIFT, PolyPhen (Flanagan et al., 2010) and MutationTaster 
(Schwarz et al., 2014). The GEMINI program was also utilized for variant analysis (Paila 
et al., 2013) 
 
2.2.6.3 Illumina 
Illumina whole exome sequencing (exome capture kit SureSelectXT V5+UTR; 
TheragenEtex, Korea) was performed on 2 affected family members (D4 and D8). All 
exomes were >90% covered to >20-fold. The file processing from FASTQ to VCF was 
performed as per the GATK best practices guidelines version 3.6 
(https://software.broadinstitute.org/gatk). Variant annotation was performed with in-
house scripts using the ANNOVAR and GEMINI software programs, as per the Ion Proton 
section described above.  
 
2.2.7 Linkage analysis 
Variants were extracted from the Ion Proton whole exome sequencing data using the 
vcf2linkdatagen.pl script from LINKDATAGEN (Bahlo & Bromhead, 2009) to infer 
genotypes at the location of HapMap Phase II SNPs (https://www.ncbi.nlm.nih.gov /pmc/ 
articles/ PMC2689609/). This allows linkage analysis to be performed without requiring 
genotyping arrays. Mendelian inheritance errors were identified and removed. MERLIN 
(Abecasis et al., 2002) was used to perform parametric multipoint linkage analysis, using 
a fully penetrant dominant disease model. Linkage calculations were performed using an 
assumed disease allele frequency of 0.0001.  
 
2.2.8 Variant confirmation and prioritization 
Variants identified were prioritized according to likely functional relevance to 
Dupuytren’s pathology and the predicted pathogenicity of the variants. Pathogenicity of 
single nucleotide variants was estimated by the use of the SIFT, PolyPhen2 and Mutation 
Taster tools (Adzhubei et al., 2010;  Schwarz et al., 2010;  Sherry et al., 2001). For selected 
variants PCR and Sanger sequencing confirmation of the presence/absence of the variant 
in affected/unaffected family members was used.  
 
 
2.3 Results 
 
2.3.1 Genes identified using the SOLiD platform 
 
The initial experiment involved WES of 3 affected family members using the SOLiD 
platform. This process identified four hundred variants common to all three family 
members sequenced. This number was significantly reduced by selecting only those that 
were both non-synonymous (therefore more likely to be disease causing) and 
heterozygous (given the autosomal dominant nature of inheritance). Also by using two 
custom variant-filtering steps: (1) one against the 1000 Genomes database (February 2012 
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release) and eliminating any variants detected in >1% of the population, and (2) one 
against the dbSNP135 common database and again eliminating any common SNPs 
identified. This resulted in a final list of 43 identified genes containing non-synonymous 
heterozygous mutations (Table 2.1). 
 
For further family member sequencing a subset of this total (9 candidates) was selected. 
The list was refined by using biological databases to identify those genes with the most 
likely relevance to what is known of Dupuytren’s pathology (for example search terms 
included collagen deposition/secretion; skin; male hormones; diabetes). Databases 
(including ENSEMBL and Genecards) were both used to investigate gene function. In 
addition each mutation was assessed for likely deleterious impact using in silico predictive 
tools. A list of nine candidate genes was ultimately selected using this approach (Table 
2.2).  
 
Table 2.1: list of candidate genes from WES analysis. Final candidate gene list with all genes containing a non-
synonymous heterozygous variant as outlined in the methods section.These genes were identified by comparative 
analysis of only affected family member DNA samples. 
All 43 genes contain a non-synonymous variant and are heterozygous in the family 
members analysed by WES 
 
GENE NAME GENE NAME GENE NAME GENE NAME 
ADAM15 FAM1882 PLXNA2 WDR64 
AGPAT5 GBA3 POLR3A ZFYVE27 
AKAP8 HSD3B1 PTPRD PKD1L3  
ANKRD31 ICAM1 RNF169 EXOC6B 
BORA JHDM1D S100A7L2 VPS41 
C1orf204 KCNV2 SERPINA1 PDCD11 
CCDC80 KLF11 SPHK1 EMR4P 
CDRT4 KRT24 TUFT1 VPS37A 
CNTN5 MED1 uc021qtm OR4C3 
COBL MX2 VAV1 DNR 
CYP2F1 NDUFS2 VPS13A  
 Table 2.2: Selected mutations for intial SNP analysis 
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2.3.1.2 PCR fragment sequencing in additional family members 
Sanger sequencing was then conducted on short fragments containing each gene mutation 
in additional family members. Heterozygous mutations were identified by the presence of 
two alternate reads at the single nucleotide position (Figure 2.2A). Non-affected and 
affected family members were sequenced. 
 
None of the identified mutations segregated with the affected members of the family 
(Table 2.3). All mutations were not present in at least 2 affected family members, except 
for the ADAM15 gene mutation that was only not present in one affected family member 
(Table 2.3). 
 
 
Figure 2.2: Sanger sequencing in family members for heterozygous non-synonymous variants in selected genes.  
Heterozygous nucleotides are identified by the presence of two peaks at the individual sequencing site being investigated 
(A), compared to the single peak observed for homozygous nucleotides (B). Arrow indicates nucleotide position of 
interest. 
 
 
 
 
No variants segregated in all affected family members (Y is a positive sample containing 
heterozygous variants, and N is a sample not containing the heterozygous variant). 
 Table 2.3: Sanger sequencing of putative causative variants in additional affected and non-affected family members 
No identified genes contained the SNP of interest in all affected patients tested and mutations were 
identified in family members that continue to be unaffected at the time of the study making them unlikely 
candidates. 
 
Prior to assessing other candidate variants in the family an additional clinical visit was 
made to confirm diagnosis of those family members that were affected. During this 
revisiting process a family member was identified that had been incorrectly classified as 
an affected family member when there was no evidence of the disease at the follow-up 
visit. Therefore additional WES was then conducted on 2 other family members that were 
identified as affected during the clinical visits.  
 
2.3.2 Genes identified using the Ion Proton sequencing platform 
The misdiagnosed exome sequence was removed from analysis and the identification 
process was repeated, this time using the Ion Proton sequencing platform. This resulted in 
a list of 28 variants being identified that were common to all four affected exomes 
sequenced (Table 2.4). All four affected family members sequenced for this analysis were 
positive for Dupuytren’s disease at the follow-up clinical visit.  
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Table 2.4: Variants identified in 4 family members by WES 
List of 28 variants identified by WES of four affected family members with Dupuytren’s disease (all variants were 
heterozygous and present at <0.1% in the ExAC database). Table shows Chromosomal location, reference and actual 
base at this position, gene name, type of mutation and the % present in the ExAC database.  
 
Chr Start Ref Alt Gene Mutation ExAC 
1 228596057 C T TRIM17 non-synonymous SNV 0.0002 
10 135368906 G C SYCE1 synonymous SNV 0.0041 
13 52693478 A G NEK5 nonsynonymous SNV 0.0001 
13 46562926 C T ZC3H13 synonymous SNV 0.0089 
15 63014680 G A TLN2 synonymous SNV 0.0032 
17 8167600 TG GC PFAS non-frameshift 
substitution 
absent 
17 4462264 G A GGT6 synonymous SNV 0.006 
18 47778134 C T CFAP53 non-synonymous SNV 0.0024 
22 19750797 C T TBX1 synonymous SNV 0.003 
3 169485336 A G ACTRT3 non-synonymous SNV 0.0033 
3 130107567 T G COL6A5 non-synonymous SNV 0.0034 
3 52383001 G A DNAH1 non-synonymous SNV 0.0049 
3 38565782 C T EXOG non-synonymous SNV 0.0019 
3 39145040 T C GORASP1 non-synonymous SNV 5.04E-05 
3 52836533 G A ITIH3 non-synonymous SNV 0.0087 
3 129150385 C G MBD4 non-synonymous SNV 0.0054 
3 140401440 C T TRIM42 non-synonymous SNV 0.0009 
3 165547451 C T BCHE synonymous SNV   
3 169555275 A G LRRIQ4 synonymous SNV 0.0045 
3 52507794 G A NISCH synonymous SNV 0.0052 
3 51458183 G A VPRBP synonymous SNV 0.0074 
4 73935320 A G COX18 non-synonymous SNV 0.0052 
6 31238909 GT AG HLA-C non-frameshift 
substitution 
Absent 
 2.3.2.1 Linkage analysis 
Of these 28 variants identified, 17 were non-synonymous (Table 2.4). In addition to the 
identification of variants of interest, linkage analysis was also used to screen for regions 
of positive linkage and also to screen those regions that were definitely not linked to the 
disease (Table 2.5. Fig. 2.3).  
7 24910408 T C OSBPL3 synonymous SNV 0.0051 
9 136419629 G A ADAMTSL2 non-synonymous SNV Absent 
9 130472886 A G CFAP157 non-synonymous SNV 0.0002 
9 130265116 C T LRSAM1 non-synonymous SNV 0.0001 
9 126213026 T C DENND1A synonymous SNV 0.0007 
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Table 2.5: Linkage analysis to 
eliminate candidate genes. 
Only 14 potential candidate 
genes remain after screening 
 
Regions could be 
elimitated using linkage 
scores across this 
chromosome, leading to 
the removal of VPRBP, 
DNAH1, NISCH and 
ITIH3 as potential 
candidate genes due to 
their location within 
negative regions (Table 
2.5, Figure, 2.3). The 
remaining list contained 
14 potential candidate 
genes. Of these, only 
EXOG and GORASP1 
were within regions with 
positive linkage scores 
(Table 2.6). 
 
CHR POS LABEL LOD ALPHA HLOD 
3 0.5876 rs969818 0.9017 1 0.9017 
3 0.5957 rs7634545 0.9019 1 0.9019 
3 0.5974 rs3796187 0.9019 1 0.9019 
3 0.601 rs4234259 0.902 1 0.902 
3 0.6044 rs1118148 0.9021 1 0.9021 
3 0.6071 rs6809649 0.9022 1 0.9022 
3 0.6105 rs2070488 0.9022 1 0.9022 
3 0.6122 rs1805124 0.9023 1 0.9023 
3 0.6156 rs6599250 0.9023 1 0.9023 
3 0.6209 rs2270770 0.9025 1 0.9025 
3 0.6272 rs1714414 0.903 1 0.903 
3 0.6387 rs1716979 0.9009 1 0.9009 
3 0.6405 rs3733053 0.9006 1 0.9006 
3 0.6459 rs40416 0.899 1 0.899 
3 0.6489 rs2240859 0.8972 1 0.8972 
3 0.653 rs3772165 0.8921 1 0.8921 
3 0.6622 rs4682960 -0.1603 0 0 
3 0.6641 rs2037358 -0.2649 0 0 
3 0.6716 rs2248991 -3.398 0 0 
3 0.6732 rs2742399 -3.3786 0 0 
3 0.677 rs11130097 -3.398 0 0 
3 0.6798 rs4082155 -3.2509 0 0 
3 0.6822 rs1062633 -3.0446 0 0 
3 0.6867 rs352166 -3.0897 0 0 
3 0.6895 rs2230493 -3.1819 0 0 
3 0.691 rs6805302 -3.3981 0 0 
3 0.6939 rs2250736 -3.3365 0 0 
3 0.6973 rs4687757 -3.398 0 0 
3 0.7098 rs6782115 -3.3467 0 0 
The LOD score was calculated for individual SNPs across a region of chromosome 3. 
SNPs were assessed for positive (green), neutral (yellow) or negative (pink) LOD scores.  
 
 Figure 2.3:  Linkage analysis of individual chromosomes. 
Linkage analysis identifies positive and negative regions in WES of 4 affected family members. a/b show 
regions across Chromosome 3, which could then be used to eliminate candidate genes within the negative 
regions, including VBPRBP and DNAH1.  
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Table 2.6: Non-synonymous variants remaining after removal of those with a negative linkage score 
Genes highlighted in bold are those with a positive linkage score, other genes not in bold were not 
excluded by linkage analysis. 
 
Chr Start Ref Alt Gene Mutation ExAC 
1 228596057 C T TRIM17 non-synonymous SNV 0.0002 
13 52693478 A G NEK5 non-synonymous SNV 0.0001 
18 47778134 C T CFAP53 non-synonymous SNV 0.0024 
3 169485336 A G ACTRT3 non-synonymous SNV 0.0033 
3 130107567 T G COL6A5 non-synonymous SNV 0.0034 
3 38565782 C T EXOG non-synonymous SNV 0.0019 
3 39145040 T C GORASP1 non-synonymous SNV 5.04E-05 
3 129150385 C G MBD4 non-synonymous SNV 0.0054 
3 140401440 C T TRIM42 non-synonymous SNV 0.0009 
4 73935320 A G COX18 non-synonymous SNV 0.0052 
9 130472886 A G CFAP157 non-synonymous SNV 0.0002 
9 130265116 C T LRSAM1 non-synonymous SNV 0.0001 
 
12 genes were identified after refinement by linkage analysis, and only two were in regions 
of positive linkage (shown in bold). 
 
2.3.2.2 In silico prediction 
Using in silico prediction, the likelihood of each mutation being deleterious was assessed 
(Table 2.7). None of the 12 variants were predicted to be deleterious by all in silico 
analyses. The gene with the highest predicted value for being deleterious, and predicted 
to have a high impact on protein function, was COL6A5. Given the well-established 
importance of other collagen types in fibrosis, this gene was therefore investigated further. 
In addition, given that both GORASP1 and EXOG were also predicted to be potentially 
deleterious and were found in regions of positive linkage, these variants were also 
investigated further. 
Table 2.7 In silico prediction of the likelihood of non-synonymous variants being deleterious to function. 
Use of in silico predictive tools to identify deleterious mutations and prioritise further analysis showed 
consensus across three different in silico platforms (SIFT, Polyphen and Mutationtaster) that the genes in a 
region of positive linkage contained mutations likely to be deleterious (D =deleterious, B or N benign or 
non-deleterious mutations; L and M suggest Low/Medium impact of the mutation) 
 
 
COL6A5 has the highest level of prediction to be deleterious across all predictive 
programs, and the variant was also predicted to have a high impact on protein function by 
Mutation Assessor scoring (Predicted types of mutation; T - tolerated, B - benign, D - 
deleterious; Impact of mutation predicted by Mutation Assessor as; L – low, M - medium, 
H – high). 
 
2.3.2.3 Sequencing of COL6A5, GORASP1 and EXOG fragments in family members 
To investigate whether these variants segregated within the family with Dupuytren’s 
disease, Sanger sequencing of PCR fragments was conducted using multiple family 
samples. Sequencing was focused on 3 candidate genes. GORASP1 and EXOG were both 
selected due to their identification in a region of positive linkage from initial analysis. In 
addition COL6A5 was selected for sequencing due to the fundamental link between 
collagen deposition and fibrotic disease. Initial sequencing showed that no variant 
segregated with the disease in additional family members (Fig. 2.4). Interestingly, no 
family member tested appeared to have a COL6A5 variant present (Fig. 2.4). Given the 
large number of siblings within the family being tested it was unusual to observe no 
heterozygotes in the PCR analysis. Investigation of the sequence underlying the original 
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primers used for PCR demonstrated the presence of additional SNPs that may have 
disrupted the amplification ability, leading to detection of only the wildtype allele. 
Therefore additional primers were designed and COL6A5 was again sequenced. However, 
COL6A5, whilst positive for the variant in some family members, did not segregate with 
the disease in all family members tested, suggesting this variant is not disease-causating 
in the family being investigated (data not shown). 
 
Figure 2.4: Sanger sequencing of candidate gene fragments in additional family members.Sequencing of 
COL6A5 (A), GORASP1 (B) and EXOG (C) fragments in additional family members. No mutation appears 
positive in all disease positive family members tested. COL6A5 appears to have no heterozygotes present 
when tested with this primer set. 
 2.3.4 Genes identified using the Illumina platform 
Illumina WES (exome capture kit SureSelectXT V5+UTR; TheragenEtex, Korea) was 
performed on DNA from two affected family members (D4 and D8). The variants 
identified using this platform included twelve new candidates (Table 2.8) in addition to 
those previously found by the use of SOLiD and Ion Proton sequencing platforms.  Of the 
twelve novel variants identified using the new platform, none had been previously 
identified using other platforms, even if restricting the comparative sequencing to the two 
members sequenced using the Illumina platform (D4 and D8 only). Of the new genes five 
have previously been recorded in association with clinical conditions exhibiting 
inflammatory changes and immune reactions. No further investigation of these genes was 
undertaken at this point as a novel approach to triangulate alternative data sources was 
undertaken to further investigate the mutations underpinning Dupuytren’s disease. 
 
Table 2.8: Additional genes identified that contained non-synonymous variants in family members sequenced using 
the Illumina WES platform. 
Gene Name Gene Name 
Gene 
Name 
Gene 
Name 
Gene 
Name 
Gene Name 
ALPI CYP2T3P IRGC PIK3R4 TCP11X3P TRIM21 
ANKRD36BP HSPA12B MEX3D PSG8 TOLLIP VNN3 
 
The use of an alternative sequencing platform highlights new variants of interest, 
demonstrating the differences arising from the platform used. A number of these genes 
are related to inflammatory diseases, suggesting a possible role in Dupuytren’s disease. 
 
2.3.5 Summary 
WES of family members with diagnosed Dupuytren’s disease was used to investigate the 
presence of non-synonymous variants within the family that may be causative. Using three 
alternative sequencing platforms with subsequent PCR sequencing for mutations in the 
wider family, no individual variant was found to segregate with the disease in this family.  
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2.4 Discussion 
 
2.4.1 Non-synonymous variants identified by WES in a family with Dupuytren’s 
disease 
The data from the WES analysis of four related, affected individuals using the Ion Torrent 
platform identified non-synonymous heterozygous variants in 12 candidate genes that also 
conformed to the selection criteria. The three candidate genes that either showed positive 
linkage (GORASP, EXOG) or were known to have a strong likely functional link to 
fibrosis (COL6A5) were all subsequently tested using PCR for segregation within the 
family. None of the variants tested was shown to segregate with all affected members of 
the family, thereby ruling out these variants as being disease-causing. Therefore other 
variants identified should be followed up for this study.  
 
COL6A5 was indicated as a strong possible candidate gene from the lists of genes 
containing non-synonymous variants due to the well-known important role of collagen in 
fibrosis (Wynn Ta, 2008). The COL6A1 subunit has previously been shown to be elevated 
in expression in Dupuytren’s tissue (Shih et al, 2009) and therefore other subunits of 
COL6 are potentially strong candidates. Collagen VI is a component of the extracellular 
matrix of almost all connective tissues, including cartilage, bone, tendon, muscles and 
cornea, where it forms abundant and structurally unique microfibrils organized into 
different suprastructural assemblies. The precise role of collagen VI is not clearly defined 
although it is most abundant in the interstitial matrix of tissues and often found in close 
association with basement membranes (Fitzgerald et al 2013). 
 
A recent paper reviewing ‘Collagen Type VI-Related Disorders’ (Lampe, Flanigan, et al; 
2004; 2012) discusses the clinical characteristics of several disorders that represent a 
continuum of overlapping phenotypes. These include Bethlem myopathy and Ullrich 
congenital muscular dystrophy (CMD) and two rare, less well-defined disorders, 
specifically autosomal dominant limb girdle muscular dystrophy and autosomal 
recessive myosclerosis myopathy. These phenotypes however share little overlap with 
Dupuytren’s disease, and the subsequent findings that family members positive for the 
disease did not all share the mutation identified by WES suggest that this variant is 
unlikely to be causative for Dupuytren’s in this family. 
 
However, it is important to consider that the lack of segregation does not necessarily 
preclude the variants from being important in the pathology of Dupuytren’s disease. It is 
possible, for example, that an individual member of the family could be positive for 
Dupuytren’s disease due to a somatic rather than an inherited mutation, particularly since 
Dupuytren’s disease is a relatively common disease. This would effectively mask the 
disease-causing mutation in most family members by providing a positive phenotype 
without the inherited mutation. It is also possible due to incomplete penetrance that there 
are members of the family who are ‘carriers’ of the causative mutation(s) but do not 
express the Dupuytren’s disease phenotype due to different environmental influences. 
Therefore, it is important to consider the genes identified as containing rare variants for 
potential functional relevance to the pathophysiology of Dupuytren’s disease.  
 
The first list of potential candidates needed to be discarded due to errors in diagnosing 
family members, highlighting the importance of clinical diagnoses in genetic studies. 
Fortunately, the individual WES data for each person was still accurate and new 
comparative analyses could be performed based on the revised clinical diagnosis of the 
family member in question.  
Subsequent to the Ion Proton sequencing used for 4 family members the additional 
Illumina sequencing of two affected individuals provided a list of a further 12 candidate 
genes with non-synonymous rare variants. These 24 potential candidate genes will need 
to be further investigated, with the focus initially on the 21 genes not yet investigated. 
Interestingly, the genes containing variants that may be associated with the disease appear 
to comprise subsets of genes with similar roles/functions. This may indicate the 
importance of certain processes in the pathogenesis of Dupuytren’s disease in this family.  
 
Many of the genes containing non-synonymous variants have functions related to 
angiogenesis, immune responses and neural functions. Many of these processes have 
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important and well-established roles in wound healing and fibrosis, suggesting that the 
genes with non-synonymous variants may be good candidates for futher investigation. 
Indeed, whilst it is clear that fibroblasts play an important role in fibrotic disease, it has 
also been suggested that rather than fibroblast dysfunction being the driver of fibrosis, it 
is external triggers of fibroblast collagen production that are altered (Fig. 2.5). As outlined 
in Figure 2.5, it has been shown that external signals impact significantly on fibroblast 
function and fibrosis. For example, keratinocytes have been shown to be important in 
keloid disease, whereby it is the epithelial cells that appear to drive the disease rather than 
changes to the fibroblasts. Similarly, immune drivers of fibrosis such as in sclerosis also 
occur external to the key collagen producing fibroblasts. Therefore, it is possible that the 
mutations that underpin Dupuytren’s disease exist in the current shortlist of candidate 
genes and influence the disease through an indirect influence on fibroblast activity. The 
possible role for these genes that have not been tested and the evidence for their likely 
involvement in Dupuytren’s pathogenesis are discussed in more detail below. 
 
 
Figure 2.5: Factors influencing fibroblast differentiation and function. 
Diagram illustrating the potential role for other physiological processes to influence 
fibroblast function and ultimately fibrosis in Dupuytren’s disease. 
 
2.4.2 Genes involved in angiogenesis 
The HSPA12B gene has an important role in endothelial cells and in angiogenesis 
(Steagall et al., 2006). Angiogenesis is an important process in tissue damage repair and 
has been implicated in fibrosis, although the role of angiogenesis remains controversial 
(Hanumegowda et al., 2012). It has been postulated that increased angiogenesis plays an 
important role in progressive fibrosis such as keloid scar formation (Zhang et al., 2015), 
but equally there is evidence that a lack of angiogenesis can induce hypoxia and a fibrotic 
response in damaged tissue (Lokmic et al., 2012). Despite the unclear role for 
angiogenesis in contributing to fibrotic disease, it is possible that this process is important 
in the progression or initiation of fibrosis. HSPA12B has also recently been shown to be 
protective against cardiac damage in a model of myocardial infarction (Li et al, 2013). In 
this study HSPA12B attenuated tissue damage through promotion of more rapid 
vascularization of damaged tisse and therefore faster repair. Therefore it could be 
hypothesized that a mutation in this gene could lead to increased or decreased 
vascularization, dependent on the mutation type, in response to the damage to tissue 
caused by extensive use of the hands over many years. A link between Dupuytren’s 
disease and vascular supply has previously been hypothesized due to the correlation 
between type II DM and the incidence of Dupuytren’s disease. Therefore HSPA12B 
remains a candidate gene for further investigation.  
 
2.4.3 Genes with roles in inflammatory processes 
Studies of genetic variants associated with susceptibility and mortality of idiopathic 
pulmonary fibrosis (IPF) have identified several rare mutations and one common SNP of 
MUC5B (Noth et al, 2013). Through a large international consortium and a genome-wide 
association study variants associated with the TOLLIP and SPPL2C genes were also found 
to be associated with IPF susceptibility. These associations and the reduced expression of 
TOLLIP in patients with IPF who carry TOLLIP SNPs emphasise the potential importance 
of this gene in IPF. The TOLLIP mutation identified by the Illumina platform in the 
affected Dupuytren disease family members has previously been reported in 
lymphoproliferative syndrome and inflammatory signaling (Cohen, 2014). Therefore 
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given the role of TOLLIP in IPF and its importance to immune function it is also a strong 
potential candidate gene for Dupuytren’s disease. 
 
The genes IRGC, TRIM21 and VNN3 are all commonly highly expressed in a number of 
inflammatory and immune-related disorders. VNN3 is one of two members of the vanin 
gene family found to be induced at the mRNA and protein level by psoriasis-associated 
pro-inflammatory cytokines (Jansen et al., 2009), whilst TRIM21 has been investigated 
both for its role in physiological and pathological immunity (Yoshimi, 2012; McEwan, 
2016). TRIM21 has been shown to be protective against aberrant protein accumulation in 
a model of Alzheimer’s disease, whilst TRIM21 is also known to have potent anti-viral 
effects. Given the diversity of roles for these genes and their importance to immune 
function it is reasonable to expect that significant mutations in these genes would lead to 
a more widespread phenotype than observed. Nevertheless there is evidence that the 
immune system may be an important contributor to the initiation of Dupuytren’s disease 
and these genes require further investigation.  
 
2.4.4 Candidate genes with neural functions 
The third ‘cluster’ identified appear to be genes associated with neural function. Whilst to 
date there is little evidence for a role of peripheral nerves in the development of 
Dupuytren’s disease, cutaneous innervation is well known to be important for wound 
healing and some recent evidence exists for a role in hypertrophic scar formation (Li, 
2015; Lavardet, 2015; Roosterman, 2006; Cheret, 2013). Therefore it is important to 
assess mutations in genes with important roles in peripheral nerves as these may play an 
as yet unidentified role in Dupuytren’s pathology. The LRSAM1 gene identified in this 
study has previously been associated with Charcot Marie Tooth (CMT) syndrome. This 
disorder begins with atrophy and weakness of distal muscles in the leg (e.g. peroneal), 
advancing insidiously to involve other muscles of the leg and arm. The hereditary 
polyneuropathy affects both sensory and motor pathways with disparate clinical 
presentations.  
 
Peripheral neuropathy is a clinically variable and genetically heterogeneous disease. In a 
cohort of patients Gonzaga-Jauregui et al. identiﬁed causative variants in 45% of the 
families studied, proposed candidate disease genes for an additional three families, and 
recognized a signiﬁcant variant burden in patients versus controls that likely contributes 
to phenotypic variability (Gonzaga-Jauregui et al., 2015). Whilst Dupuytren’s patients do 
not present with peripheral neuropathy, other peripheral nerve dysfunction may be 
important. For example the role that peripheral nerves can play in inflammation and the 
immune response may be important, similar to the studies to date suggesting immune 
dysfunction is central to the disease. However, at present with the limited evidence for an 
impact of innervation on Dupuytren’s disease candidate genes with functions relevant to 
peripheral nerves should be prioritized lower than those involved in other processes with 
stronger evidence such as the immune and vascular response. 
 
 
2.4.5 The absence of genes identified in previous studies 
The only known genome-wide analysis from members of one family of Dupuytren’s 
affecteds is the extensive investigation of a five generation Swedish family with autosomal 
dominant inheritance of the disease, reported by Hu et al. (2005). These investigators 
established linkage to a single 6cM region between markers D16S49 and D16S3032 on 
Chromosome 16q. There is no evidence from the current study to confirm this finding 
with no mutations observed in genes within this region. 
 
Similarly the GWAS of 960 unrelated Dutch persons with the Dupuytren’s phenotype 
yielded an association with 11 SNPs from 9 different loci, six of which contain genes 
known to be involved in the Wnt-signalling pathway ie WNT4, SFRP4, WNT2, RSP02, 
SULF1 and WNT7B. No mutations were found in any of these genes in the current 
investigation. 
Meanwhile, several studies of gene expression analysis in Dupuytren’s disease, based on 
cord tissue samples from affected hands, have identified a larger number of genes with 
dysregulated expression levels in Dupuytren’s tissue (Zhang et al., 2008; Forrester et al., 
2013). However no mutations in the genes with the most significant differences in 
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expression in these studies (for example in top 50 upregulated and down-regulated in 
Forrester et al) were found in this family. 
 
As with many conditions where there is phenotypic variance, in this case related to age of 
onset, palmar involvement, degree of digital contractures, rate of progression of 
fibromatosis and racial differences, there is reason to consider multiple gene involvement 
and that it is changes to similar pathways that likely underlie the disease rather than 
common specific mutations in an individual gene or genes. It is also important to consider 
with the expression studies that the genes identified as being most dysregulated may not 
be related to the cause of the disease but rather their dysregulation may be a consequence 
of the disease, thus explaining the disparity between genetic studies and expression studies 
of this disease. Given the importance of environmental factors, the use of different 
populations in these studies compared to the West Australian family in this current study 
and the different approaches used it is not surprising that overlap has not been observed. 
However, WNT signaling has been extensively implicated in Dupuytren’s disease, and 
the absence of any genes with known critical functions in WNT signaling in this study is 
surprising. This may be due to the limitations of this study approach and the restrictions 
used in identifying mutations of interest (see section 2.4.7). 
 
2.4.6 The advantages of using WES to identify causative mutations 
One of the advantages of using a genetic approach is that it is potentially feasible to 
identify the trigger for Dupuytren’s disease. This is in contrast to a second common 
approach that uses diseased tissue as the source material for identifying transcriptome or 
proteomic changes related to Dupuytren’s disease. Because the use of diseased tissue 
invariably involves cells that have been cultured or isolated it is very difficult to identify 
causative changes as opposed to consequential changes. This is particularly true in 
diseases that are generally treated surgically at quite a late stage such as Dupuytren’s 
disease, where the time between disease initiation and obtaining tissue is substantial. 
During this period it is likely cells undergo many changes in phenotype and expression 
and therefore identifying the causative changes is a significant challenge.  
 
The essential benefit of WES is its selective focus on the part of the genome encoding for 
proteins to identify non-synonymous mutations that are likely to affect protein function 
and therefore underlie disease. While only functional mutations (rather than those 
affecting expression levels, for example within promoter regions) can be identified, it 
reduces significantly the number of data points identified and therefore is more likely to 
be able to find disease-causing mutations. WES is restricted to mutations that change the 
coding sequence (although they can be synonymous) and therefore whilst this restricts the 
number of data points it also provides an opportunity to identify functional mutations in 
smaller populations such as the family investigated here. 
 
Although Dupuytren’s disease can be sporadic, even within a pedigree exhibiting familial 
inheritance, use of the WES approach in a family cohort offers a strong likelihood of 
identifying the same disease-causing mutations in all affected samples – and similar 
phenotype of disease within the family would suggest a common cause. Compared with 
the GWAS type approach exome sequencing also provides a list of mutations with likely 
functional impact, rather than mapping results that link to likely regions of interest. This 
therefore provides a better opportunity for further functional investigation of the impact 
of the mutations and to demonstrate a functional link to the disease.  
 
WES provides the possibility of locating rare functional changes within the protein-coding 
part of the genome (the exome) as using family members means the shared DNA is 
extensive and they will have the same causative mutation – whilst the exact mutation 
identified through WES in a family cohort may not apply to all affecteds the gene and/or 
pathway will be common to others and can therefore assist in better understanding the 
disease. The GWAS approach can only find common regions across large populations, 
and is not suitable to locate rare functional mutations.                
 
2.4.7 Limitations of using the WES approach 
The use of WES as a strategy to identify disease-causing mutations has been successful in 
many diseases and continues to be a mainstay of disease SNP identification strategies 
[Biesecker et al., 2011]. However, as with all strategies currently employed there are 
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limitations to this approach that can lead to misidentification or non-identification of 
mutations linked to disease (Sims et al., 2014). Less than 2% of the human genome 
contains protein-coding sequences and these regions must undergo exon-targeting capture 
process before being sequenced to identify clinically relevant alleles.  It is important also 
to determine the coverage of these captured regions – i.e. depth of sequencing – as the 
higher the coverage the more likely the captured base will be accurate and not a false read 
due to technical error (Li et al., 2015). Inadequate coverage of certain exomes/genes could 
lead to false negatives and the omission of important variants. Equally, inadequate 
coverage can lead to false positive variant identification. As the goal of WES is to identify 
those mutations that may be potentially pathogenic it is important to have efficient 
strategies and appropriate variant analysis pipelines. Depending on filtering parameters 
applied it is possible for a pathogenic variant to be missed if it is not targeted for analysis. 
Targeted sequencing has the advantage of increased sequence coverage of regions of 
interest at lower cost and higher throughput compared with random sequencing methods. 
 
Genome sequencing could avoid some of the technical challenges faced by WES but it 
remains expensive and requires more sophisticated analysis pipelines to filter and identify 
the increased number of potential variants. Indeed, it is unlikely that whole genome 
sequencing would provide suitable candidate lists for further investigation in a small 
family centric study such as that conducted here. However, filtering much larger datasets 
from small family studies such as that becomes increasingly difficult, and the relatively 
limited knowledge of the function of all non-coding bases in the DNA increases the 
complexity of identifying changes of interest when using whole genome sequencing. 
 
Genetic variants identiﬁed using WES induce a phenotype that can vary between 
individuals in penetrance or physiological effect and may depend on (1) environmental 
factors; (2) modiﬁer genes and/or the epigenome; and (3) the additive/synergistic effect 
from another genetic variant (digenic inheritance) (Majewski et al., 2011). High-
penetrance variants induce a strong physiological effect and these alleles have usually 
been identiﬁed as causative for Mendelian monogenic disorders using linkage studies in 
families. Low penetrance variants have a weak phenotype and causative alleles are 
typically identiﬁed in large case/ control cohorts as part of the study of complex trait 
disorders. Common high-penetrance disease variants are rare as they would normally be 
eliminated from breeding populations, except in cases of balancing selection where 
heterozygotes have an advantage over homozygotes (e.g. sickle cell disease). The 
distinction between monogenic and complex diseases is therefore operational as all 
genetic variants are de-facto transmitted in a Mendelian fashion and thus amenable to 
discovery using WES, giving this technique far wider applicability than simply the study 
of rare monogenic disorders (Rabbani et al, 2014). 
 
By limiting the further investigation to those mutations known to occur in <1% of the 
general population the majority of those considered unlikely to be involved with 
Dupuytren’s disease have been excluded. It remains possible, however, particularly in 
light of subsequent findings, that one or more relevant mutations may have been excluded 
by this means.   
 
Since all of the first generation of affected family members had only one parent known to 
have Dupuytren’s disease, the mutation must be heterozygous in these patients and results 
in the familial pattern of autosomal dominance observed in the family pedigree. 
Significantly, only one previous study has proposed an autosomal recessive model for 
inheritance of Dupuytren’s disease (Bayat et al., 2003) based on a statistical analysis of 
transforming growth factor  receptor (TGFR) gene polymorphisms obtained from DNA 
sequencing of peripheral blood samples. Their conclusion, however, based upon 
investigation of a small range of candidate susceptibility genes before it was possible to 
detect candidate gene loci, was that Dupuytren’s disease “appears to be a complex 
oligogenic rather than a monogenic condition that segregates into multiple modes of 
inheritance” (see also Burge, 1999). The pedigrees of other families with Dupuytren’s 
reported in the literature strongly support an autosomal dominant pattern of inheritance 
(Gudmundsson et al., 2000). Synonymous mutations, almost by definition, will not 
usually affect translation of otherwise normal amino acid sequences to abnormal protein, 
but the possibility of interaction between multi-purpose codons (DUONS) causing 
interference with normal processing during transcription and/or translation must be 
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considered (Stergachis, 2013). The study reporting the existence of codons with dual 
function may provide a mechanism by which synonymous variants may be more important 
in disease, and suggests that the strategy employed in this chapter of only investigating 
non-synonymous mutations is limited (Weatheritt, 2013).  
 
There is indeed evidence to suggest that changes in a gene’s sequence that are silent with 
respect to protein sequence are not always silent with respect to function (Gingold & 
Pilpel, 2011). From their assessment of mutations obtained from large-scale sequencing 
of cancer genomes the authors of a recent review article have concluded that synonymous 
mutations within oncogenes represent 6-8 percent of all driver mutations due to single 
nucleotide changes, and that approximately half of synonymous drivers alter splicing, 
which in turn may influence cancer progression (Supek et al., 2014) Of further relevance 
is the fact that synonymous mutations can also alter protein folding, thereby contributing 
to tumour progression (Kimchi-Sarfaty et al., 2007; Zhang et al., 2009; Zhou et al., 2013). 
 
Selection of priority genes of interest was based on either gene function being known to 
be relevant to Dupuytren’s pathology (for example ADAM15, KLF11); genes known to be 
involved or expressed in relevant cell types (for example CDCC80 expression in 
fibroblasts); genes that had been linked to conditions also linked by epidemiology to 
Dupuytren’s disease (for example JHDM1D) and genes that had previously been 
identified or were similar to those identified in other studies of Dupuytren’s disease (for 
example ADAM15). This selective process creates the potential for the elimination of other 
mutations that may be critical, but is necessary to restrict further investigation to a list that 
can be interrogated more fully. Nevertheless it is an important limitation that may lead to 
the omission of important mutations in this study. 
 
2.5 Summary 
Within the family members currently investigated a limited number of mutations 
potentially relevant to Dupuytren’s disease have been identified. However no overlap with 
the studies of others was identified and no mutations that were sequenced in other family 
members appeared to segregate with the disease phenotype. Therefore it has not been 
possible at this stage to identify a causative mutation. The limitations of this approach 
include the use of WES that will exclude non-coding mutations as well as the assumptions 
made to restrict the number of mutations identified in the small number of exomes 
sequenced. Therefore additional approaches may facilitate a better understanding of the 
causes of Dupuytren’s disease in the Western Australian population. To follow-up this 
family based study the next chapter will focus on a population approach, using data 
derived from a community-based health survey in which people were identified as having 
Dupuytren’s disease. The aim of this study will be to then interrogate potential regions of 
the genome for overlap with the family study presented in this chapter to determine if a 
causative gene/mutation can be identified through the combination of these different 
approaches. 
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CHAPTER 3 
 
Aim. 2 To investigate the presence of identified mutations in a wider population-based 
cohort of people with Dupuytren’s disease. 
 
3.1 Introduction 
Genome Wide Association Studies (GWAS) use a high-density map of SNPs across the 
entire genome to localize regions of interest with respect to disease. The relative 
occurrence of specific SNPs in affected and unaffected populations is identified and 
compared to locate regions of the genome that are in high linkage disequilibrium. That is 
the region strongly associated with the presence of the disease. These studies require large 
populations of both affected and unaffected individuals to be effective in isolation.  
 
3.1.1 The Busselton Population Health Survey 
Repeated cross-sectional health surveys of adults living within the south west coastal 
community of Busselton have been carried out from 1966 to 2009, although there have 
been only two major surveys since 1990, in 1994-95 and 2005-06.  Busselton has a 
relatively stable population of predominantly European descent and participation rates 
ranged between 64 to 91 percent of eligible adults. Randomised participation was by 
invitation based on the electoral rolls with recruitment via letter of introduction and 
subsequent personal interview. The population recruited is approximately 5000 
individuals, although not all individuals were assessed for all conditions in all surveys so 
not all subsequent studies have been able to use the entire population. 
 
An essential element of the Busselton study has been the longitudinal follow-up of the 
same cohort at intervals of three to five years (Phase II)(eg Busselton Healthy Ageing 
Study, 2010; James et al, 2013). The elements of each periodic community survey have 
included a limited clinical examination, focusing on certain medical conditions which 
occur commonly and which are most likely related to lifestyle, and a comprehensive 
questionnaire in support of the long-term clinical progress through childhood and all 
stages of adulthood.  In the 1994-95 survey, at the request of Dr Pearce, two additional 
questions pertaining to the participant’s Dupuytren status (affected or unaffected) were 
included in the surveys. All adults included in the survey also submitted to examination 
of their hands for evidence of the clinical manifestations of Dupuytren’s disease. Those 
responsible for examining the hands were not trained or medically qualified and the results 
suggest a high degree of inaccuracy, thereby precluding further interpretation or analysis. 
 
The questions specific to Dupuytren’s disease were: 
1. Have you observed the appearance of palpable bands or cords in the palms or digits? 
2. Have you had surgery for Dupuytren’s disease affecting your hands? 
 
Whereas over four hundred individuals claimed to have palpable palmar bands or cords, 
suggesting a possible Dupuytren’s phenotype based on subjective self-examination, only 
forty-eight admitted to having surgery for a confirmed clinical diagnosis of Dupuytren’s 
disease. The veracity and therefore reliability of the former result must be questioned as 
it included all age groups, which suggests an incidence of Dupuytren’s disease that is not 
only highly improbable but virtually impossible. It would be difficult to relate this group 
to a cohort with a diagnosis of Dupuytren’s disease with any confidence. As their DNA 
has been made available, however, an analysis of association may be made with some 
comparisons with GWAS results from the surgically treated individuals. 
  
Subsequently, many of these same individuals have had DNA collected and analysed 
using GWAS SNP profiling as part of the Busselton study. 
Here, we have identified the affected and unaffected individuals in the Busselton study 
from their responses in the 1994-95 survey. We have then used the collected GWAS data 
on these individuals to identify regions of interest that may be associated with the 
incidence of Dupuytren’s disease in this population. Whilst the population is somewhat 
small for a GWAS study, the information gained from this approach will be integrated 
with the findings from Chapter 2 to potentially identify genes of interest using two 
separate approaches. 
 
3.2 Methods 
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Ethics approval for this study was obtained from the Busselton study committee and 
relevant institutional ethics committees (University of Western Australia Human Research 
Ethics Committee – RA/4/1/2203). 
 
3.2.1 Survey Responses 
In 1995 two questions were included in the Busselton community survey as outlined 
above. Out of a complete set of responses to the questionnaire, 409 individuals responded 
positively to question one, whilst only 48 positive responses to question 2 were received. 
Thus a cohort of 48 adults who had recorded a surgical history for Dupuytren’s disease 
(DD) was identified; 42 of them provided blood samples.  
 
Of the 409 participants whose questionnaire provided suggestive evidence of palmar 
bands, 360 (ie 90 percent) gave blood for laboratory analysis. The analysis focused on 
those with a surgical history of DD as the positive affected cohort. 
 
3.2.2 Statistical power for association analysis 
Power analysis for the 513,727 Busselton GWAS SNPs available after quality control with 
suggestive genome-wide association after correction for multiple testing (i.e. requiring a 
p-value threshold of 1.0 x 10-4), with a 10% prevalence rate, and a minor allele frequency 
of 0.19 for the risk variant demonstrates that we expect 80% power for a SNP that has an 
odds ratio ≥ 1.67 for 409 developed thickened band cases and 4,262 controls and an odds 
ratio ≥ 4.0 for 48 positive cases and 4623 controls. Although these odds ratios would be 
considered large for common variants from GWAS, these results were primarily applied 
to prioritize interrogation of WES data for Dupuytren’s disease. Gene- and pathway-
centric burden tests were employed to compensate for low statistical power in variants 
that might have been missed due to low copy number.   
  
3.3 Results 
Both a dominant model (table 3.1) and additive model (table 3.2) were used to identify 
SNPs associated with DD in the Busselton cohort. The dominant model assumes that the 
risk of the disease phenotype is equivalent between heterozygotes and homozygotes with 
the relevant polymorphism. Inheritance of Dupuytren disease within families follows a 
dominant model with incomplete penetrance. The additive model, in contrast, assumes 
increased risk in homozygous compared to heterozygous SNP presence (linear increase 
therefore a homozygous affected would have 2x the effect of a heterozygous affected). 
Using an arbitrary cut-off p value of 5 x 10-5  20 SNPs and 39 SNPs were identified for 
the dominant and additive models respectively (Tables 3.1, 3.2). Using UCSC Genome 
browser (https://genome.ucsc.edu/) a search for proximal genes was then conducted to 
identify potential genes of interest. A distance cut-off from the SNP of 50MB was used 
for identifying associated genes. Within 50MB of the SNPs identified there were 17 genes 
and 5 long non-coding RNAs (LINCs) for the dominant model (table 3.1). There were 18 
genes and 2 LINCs within this distance for SNPs identified using the additive model (table 
3.2). 
 
No genes identified using this methodology were identified that were also identified in the 
previous family study using whole exome sequencing (Chapter 2). However, genes with 
roles closely related to those identified in the previous family WES study were identified, 
including genes with known functions in immune responses, matrix remodeling and 
vascularization. This may implicate these processes in the molecular pathology of DD and 
are discussed in detail below. 
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Table 3.1:Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton population 
using the dominant model. Table shows chromosomal location, SNP (A1) at this location, Odds ratio (effect size of the 
SNP identified), p value (not corrected) and genes identified at this location using UCSC genome browser together 
with other features of that region (within 50MB DNA of SNP). 
CHR SNP BP A1 OR P Genes Other 
1 rs1938506 185647122 C 1.676 
7.06E-
06 
 
LINC01036, 
LINC 01037 
1 rs4650729 185645949 A 1.67 
8.21E-
06 
 
LINC01036, 
LINC 01037 
1 rs2755095 224266458 A 1.669 
1.42E-
05 
SDE2, 
LEFTY1, 
LEFTY2 
 
1 rs10917756 161688944 T 0.6072 
2.54E-
05 RGS5, NUF2 
 
1 rs11590226 224269676 G 1.676 
3.07E-
05 
SDE2, 
LEFTY1, 
LEFTY2 
 
3 rs926147 8665221 G 1.627 
3.58E-
05 
SSUH2 
(intragenic) 
 
4 rs2629722 19601579 C 0.5818 
1.59E-
05 none 
 
4 rs7664705 178808597 T 1.64 
3.62E-
05 
 
LINC01098, 
LINC01099 
4 rs12642843 168828864 T 0.6028 
4.15E-
05 none 
 
6 rs10946808 26341366 G 0.6045 
1.79E-
05 HIST1H1D  
Other 
histone 
proteins 
6 rs9358913 26347383 G 0.6135 
3.62E-
05 HIST1H1D  
Other 
histone 
proteins 
7 rs7806362 28353228 A 0.6222 
4.22E-
05 
CREB5 
(intragenic) 
 
10 rs704014 80502780 A 0.5601 
2.80E-
05 
ZMIZ1 
(intragenic) 
 
12 rs8176350 56443115 A 7.463 
8.93E-
06 
CYP27B1 
(intragenic) 
 
14 rs1245384 26683529 G 15.11 
1.64E-
05 mir4307 
 
14 rs1016692 68858656 G 1.654 
2.14E-
05 
GALNT16 
(intragenic) 
 
15 rs10520669 86160186 T 1.796 
3.52E-
06 NTRK3 LINC00052 
15 rs596726 60966570 C 0.5897 
4.86E-
06 TPM1, TLN2 MGC15885 
16 rs7359428 7597028 A 1.908 
3.49E-
05 
RBFOX1 
(intragenic) 
 
20 rs6084497 3778474 C 0.6093 
2.76E-
05 
MAVS 
(intragenic) 
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Table 3.2: Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton 
population using the additive model. Table shows chromosomal location, SNP (A1) at this location, Odds ratio (effect 
size of the SNP identified), p value (not corrected) and genes identified at this location using UCSC genome browser 
together with other features of that region (within 50MB DNA of SNP). 
CHR SNP BP A1 OR P Gene 
Other 
Information 
15 rs16944840 89146352 C 4.841 
1.91E-
06 
BLM (intragenic)  
18 rs8085949 38534982 A 5.477 
2.04E-
06 
 LINC00907 
15 rs8027126 89138090 T 4.772 
2.44E-
06 
BLM (intragenic)  
18 rs9963027 38540181 C 5.852 
2.82E-
06 
 LINC00907 
11 rs4944893 73848928 T 3.354 
3.55E-
06 
KCNE3 
(intragenic) 
 
11 rs11602340 73852880 G 3.305 
4.32E-
06 
KCNE3 
(intragenic) 
 
3 rs17071419 64730279 C 9.58 
4.67E-
06 
ADAMTS9-AS2  
18 rs1790605 65673014 G 3.64 
5.50E-
06 
CD226  
18 rs1469857 65679994 A 3.593 
6.35E-
06 
CD226  
2 rs1902156 84431095 T 3.709 
7.31E-
06 
none  
PYHIN8 rs11985018 23667806 T 2.985 
7.44E-
06 
 
RP11-
175E9.1 
2 rs11904045 84472093 T 3.697 
7.79E-
06 
none  
8 rs10866835 23663678 C 2.979 
7.82E-
06 
 
RP11-
175E9.1 
9 rs10117511 20291210 A 6.337 
7.99E-
06 
MLLT3  
18 rs1790942 65692568 G 3.589 
8.20E-
06 
CD226  
22 rs133681 47145275 G 2.757 
8.92E-
06 
none  
3 rs7613386 136942607 A 2.769 
1.03E-
05 
none  
3 rs17071334 64686344 T 6.85 
1.18E-
05 
ADAMTS9-AS2  
5 rs10057902 93838641 T 5.855 
1.22E-
05 
KIAA0825  
9 rs16938009 20298956 G 6.017 
1.42E-
05 
none  
4 rs10516161 57631492 G 3.829 
1.60E-
05 
IGFBP7  
5 rs2656984 82224868 C 4.297 
2.00E-
05 
none  
1 rs11590737 157210445 G 3.083 
2.09E-
05 
PYHIN1  
8 rs878422 142397180 T 2.853 
2.24E-
05 
 LINC01300 
6 rs13213906 68284933 C 2.612 
2.33E-
05 
none  
8 rs9650576 142415238 T 2.832 
2.47E-
05 
  
6 rs9454149 68213259 G 2.617 
2.62E-
05 
none LINC01300 
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8 rs10503582 16475833 C 2.741 
2.76E-
05 
none  
21 rs2032308 31287785 G 2.846 
2.95E-
05 
KRTAP21, TIAM1 
KRTAP 
cluster 
8 rs10088377 23659124 G 2.895 
3.26E-
05 
 
RP11-
175E9.1 
11 rs360145 9745546 T 7.1 
3.37E-
05 
SBF2-AS1  
10 rs675410 100340312 A 3.51 
3.57E-
05 
HPSE2  
1 rs1308343 43401913 T 5.849 
3.63E-
05 
FAM183A, 
EBNA1BP2 
 
14 rs1955967 43581549 A 2.866 
3.66E-
05 
 
RP11-
305B6.3 
6 rs7752524 25418564 G 2.939 
3.71E-
05 
LPRC16A  
22 rs138475 45408904 G 2.556 
3.85E-
05 
GRAMD4  
10 rs502195 100349453 T 3.438 
4.07E-
05 
HPSE2  
11 rs585197 88867269 C 2.597 
4.27E-
05 
NOX4  
6 rs12523876 82643081 T 3.394 
4.98E-
05 
 
RP11-
379B8.1 
 
 
 
  
3.4 Discussion 
 
3.4.1 Findings in other linkage and genome wide association studies for 
Dupuytren’s disease 
Previous genetic studies in Dupuytren’s disease have targeted those genes involved in the 
regulation of fibroblast activity, including pathological collagen production and lattice 
contraction in the extracellular matrix, as well as apoptosis and proliferation and alpha 
smooth muscle actin expression (Vi et al., 2009; Shih et al., 2012). One previous GWAS 
study has been conducted using a large population including those affected (960) and not 
affected (3117 controls) with Dupuytren’s disease (Dolmans et al., 2011). This study 
combined with three additional independent case series comprising a total of 1365 
individuals affected with Dupuytren’s disease and a further 8445 controls from Germany, 
the United Kingdom and the Netherlands to identify 35 SNPs most strongly associated 
with Dupuytren’s disease. From these large populations this study identified 11 SNPs 
from 9 regions of interest that were validated in two independent replication populations. 
Of particular interest, within 6 of these regions genes known to be involved in a single 
signaling pathway, the WNT signaling pathway, were located. This pathway has 
previously been implicated in other studies investigating the pathogenesis of fibrosis in 
Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Dupuytren’s disease, although to 
date no strong functional evidence exists to link dysfunctional Wnt signaling to 
progressive fibrosis (Moon et al., 2004; Vlad et al., 2008; Konigshoff et al., 2009; 
Bhattacharyya et al., 2012).  
Despite the large population size and independent replication populations, the previous 
GWAS study of Dupuytren’s disease has provided support for a role of specific genes but 
no actual mutations involved in Dupuytren’s pathogenesis were identified and validated. 
This is a common limitation of the GWAS approach and supports the use of multiple 
research methods combined with the GWAS approach to identify disease-causing 
mutations. 
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3.4.2 Possible role for genes in regions of interest from the Busselton GWAS study 
None of the same SNPs identified previously by Holman et al were identified in this study 
of Dupuytren’s disease although this may be solely due to limited statistical power of the 
current study. Of the genes located within regions showing positive association with SNPs 
using the p-value cut-off none have previous evidence directly linking the gene to DD. 
Howevere there were genes identified that have key biological functions related to fibrosis 
and may therefore play a role in DD. 
 
SDE2 is a Telomere maintenance homologue (S Pombe) on chromosome 1. An important 
paralog of this gene is SF3A3 which may be responsible for development of intrahepatic 
cholangiocarcinoma (Wang et al., 2006). This gene has been identified among related 
genes by comparison with normal liver tissues, but no known disorders have been found 
for the SDE2 gene. Dupuytren’s disease has a reputation for an association with high 
alcohol intake, which seems to imply a metabolic basis that could potentially be related to 
alcoholic cirrhosis (Wolfe et al., 1956). Hnanicek et al (2008) found a high incidence of 
chronic liver disease in Dupuytren’s patients but demonstrated a lack of association with 
iron metabolism in Dupuytren’s disease.  These findings, however, have not been 
confirmed consistently through large epidemiological studies, and there has been no 
positive relationship with other forms of hepatic fibrosis including haemachromatosis and 
post-hepatitis cirrhosis. Stremmel et al (1988) identified differing abnormalities in 
estrogen, androgen and insulin metabolism in idiopathic haemochromatosis compared 
with alcoholic liver disease, findings that could be relevant in Dupuytren’s pathology 
(Stremmel et al 1988). 
LEFTY2 represents Left–Right determination Factor 2 and is a member of the TGF 
superfamily. The work of Bayat (2003) and many others  has confirmed that TGF family 
members are multifunctional including a role in wound healing and fibrosis, although only 
TGFRI polymorhisms were significantly different in genotype frequency distributions 
between Dupuytren’s patients and controls. There was no statistical difference in genotype 
or allele frequency distributions between cases and controls for TGFBRII and TGFβRIII 
SNPs (Bayat et al,2003).  
The SSUH2 gene is a transcription regulator in Notch signaling and binds specifically to 
methylated DNA. It binds to the oxygen-responsive element of COX412 and activates its 
transcription under conditions of hypoxia (4% oxygen). (Aras et al 2012; Funayama et al, 
2015). Since hypoxia is a known cause of tissue fibrosis and age-related peripheral 
vascular changes, diabetes and smoking are commonly associated with the development 
of progressive palmar fibromatosis there could well be a role for this gene in the 
pathogenesis of Dupuytren’s disease. 
NTRK3 (neurotropic tyrosine kinase receptor type 3) encodes a member of the 
neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound 
receptor that, upon neurotrophin binding, phosphorylates itself and members of the 
MAPK pathway. Signaling through this kinase leads to cell differentiation and may play 
a role in the development of proprioceptive neurons that sense body position. 
In South America it has been investigated in association with Chaga’s Disease. 
Trypanosoma cruzi infestation promotes neuronal and glial cell survival (in vitro) by 
inhibiting TicC-induced apoptosis (Rodriguez and Mehlen, 2010). 
RBFOX1 has been associated with small joint osteoarthritis of the hand, familial 
neurodegenerative diseases, spino-cerebellar ataxia type 2, and in Japan it has been 
identified with primary biliary cirrhosis (Joshita et al., 2010) Its involvement with epilepsy 
could be significant in those cases that exhibit a Dupuytren’s phenotype, but the 
association of Dupuytren’s with epilepsy has not been consistently reported or confirmed. 
 
3.4.3 Comparison of results from the Busselton and family studies 
From the WES analysis of affected family members (Chapter 2) and the GWAS 
population study from Busselton there appears to be no overlap of genes identified from 
both cohorts. The two studies also do not provide overlap with other published studies 
looking at the genetic basis of Dupuytren’s disease. However in a population of unrelated 
individuals it would be expected that variable expression in terms of age of onset, degree 
of hand involvement (unilateral/bilateral), clinical evidence of digital contracture, and rate 
of progression of fibromatosis, gender differences, association with other disease profiles, 
would involve a variety of genetic pathways and genes. It is not therefore completely 
surprising that the genes obtained from such a diverse small population do not correspond 
with those identified from other studies.  
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Interestingly when comparing the family WES and Busselton study results there does 
appear to be overlap, whilst not in genes, but in the biological pathways that may be 
implicated. For example, in the WES family study (Chapter 2) a number of potential genes 
of interest that were identified had clear roles in vascularization/angiogenesis and there 
were also pro-inflammatory/immune modulating genes identified. In the investigation 
using the Busselton population data, CD226, PYHIN1 and MAVS genes which were 
proximal to identified SNPs all have roles in the immune system. In particular PYHIN1 
and MAVS are both implicated in the interferon induced anti-viral response, which is of 
interest given that previous reports have associated viral infection to Dupuytren’s disease.  
There are other very strong candidate genes identified in the list of genes proximal to the 
SNPs identified. This includes ZMIZ1, which is important in androgen receptor signaling 
and also the regulation of SMAD3/4 expression. SMAD3/4 in particular are well-known 
to be important in fibrosis and     their direct involvement in regulation of fibrosis  suggests  
a good candidate for Dupuytren’s disease.  Genes with important roles in matrix 
production and turnover were also identified including HPSE2 (a heparanase with no 
enzymatic activity but likely a regulator of other heparanase activity), TLN2 (Talin 2) and 
interestingly ADAMTS9-AS2. AS genes are anti-sense genes that are only recently 
described. The transcription of these genes appears to regulate the expression of the related 
gene, in this case ADAMTS9. The ADAM family of proteins is large and some have 
already been implicated in DD in previous studies.  
Finally, tropomyosin I (TPM1) is also a potentially interesting candidate for further 
investigation. Tropomyosin is critical in regulating actin-myosin interactions and 
contractile activity. It is clear this activity could be important in the progression of DD. 
Despite this study being underpowered the candidate genes identified in proximity to 
SNPs associated with the DD phenotype do appear to have functional roles that are 
important in DD pathology. However, the fact the study is underpowered reduces the 
significance of any individual finding and further validation that these genes may be 
involved is critical. This also highlights the difficulty of GWAS type approaches, since 
these genes are only implicated by proximity to these SNPs in the same way as WNT 
pathway genes were implicated in the much larger GWAS conducted by Dolmans et al 
(2011).  Therefore, whilst these genes are potentially of interest there is no clear functional 
or expression difference to verify that the genes identified are altered in DD affected 
patients.  The finding that many of these genes have roles in pathways also identified in 
the WES study (Chapter 2) and in other studies of DD, including angiogenesis and the 
likely role of hypoxia/circulation in DD pathology, support a non-fibroblast origin of DD 
pathology that has previously been hypothesized. 
 
3.4.5 Significance of environmental factors and genetic susceptibility 
Numerous environmental and genetic studies of the fibromatoses and related pathologies 
have produced evidence to support the familial nature of these conditions in the majority 
of cases. Inheritance of a susceptibility to develop a Dupuytren’s phenotype after middle 
age appears to follow an autosomal dominant pattern with variable expression and 
occasionally incomplete penetrance. The ethnic differences which demonstrate consistent 
but widely different incidence of Dupuytren’s pathology are most obvious between white 
Caucasians from Northern Europe and black Africans. The same difference in incidence 
exists between black and white communities living in the same country such as the United 
States. This would strongly suggest a predetermined genetic susceptibility that exists 
within the white population and to a far lesser degree among African Americans. A similar 
discrepancy exists between Europeans and most Asian populations. 
With some allowance to be made for differences in lifestyle factors such as diet, climate, 
education, employment and living conditions, it is obvious that even the susceptibility to 
develop a particular disease must be genetically determined. From the many genetic 
studies that have attempted to identify genetic pathways and specific candidate genes 
responsible for the progression of fibrosis in a Dupuytren’s phenotype it has become 
obvious also that there must be several genes and pathways involved in this pathology, 
the spectrum of such combinations accounting to some extent for the variations observed 
in age of onset and degrees and speed of progress of the disease. 
The experience of many epidemiologists tends to favour a range of environmental factors 
which might trigger the onset of Dupuytren’s, many of which can be related to the ethnic 
variations and differences in incidence observed (Geohegan et al., 2004; Gordon,1954). 
Lifestyle factors such as smoking and alcohol abuse, both of which have been associated 
with significant levels of Dupuytren’s in certain populations, tend to be related to gender, 
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age, generation and employment, factors which affect the expression of this disease to a 
variable extent in different communities (Godtfredsen et al., 2004; Khan et al., 2004). 
Nevertheless, as with a number of co-morbidities that impose further metabolic and 
immunologic stresses on molecular function, the importance of environmental impact 
upon a susceptible organism must be significant. 
“Transforming growth factor  is the pre-eminent signal for connective tissue synthesis, 
and is considered as a ‘core pathway’ in both normal wound healing and pathological 
fibrosis” (Bhattacharyya et al., 2012). However, the molecular pathways responsible for 
activation and progressive proliferation of fibroblasts and myofibroblast differentiation 
can be expected to involve a number of intrinsic and extrinsic cellular factors, including 
dysregulated beta-catenin and Wnt signaling glycoproteins (Vlad et al 2008), Akt and 
integrin pathways, and aberrant or dysregulated TGF-beta expression. Dysregulation may 
also be stimulated external to the fibroblasts which are clearly the drivers of the 
progressive disease. 
The role played by TGF receptors in the genetic susceptibility to Dupuytren’s disease 
has previously been investigated with a statistically significant difference of TGFbR1 
polymorphisms in DD in the recessive model. (Bayat 1;2003 These authors also conclude 
that “DD appears to be a complex olygenic rather than a monogenic condition that 
segregates into multiple modes of inheritance”) (see also Burge P Genetics of DD Hand 
Clinics 1999;15(1):63-72) re proposed autosomal recessive mode of inheritance). While 
the recessive model is not in agreement with the majority of observed series reported with 
familial Dupuytren’s disease the suggestion of a complex polygenic inheritance involving 
several pathways is readily accepted in light of the variable expressivity and degree of 
phenotypic progression (Hu et al., 2005; Gudmundsson et al., 2001). The role of TGF 
beta2 in this pathology has been investigated also by Zhang et al (2008) with ‘gene 
expression analysis’; different isoforms of TGF-beta have been reported to have both 
profibrotic and antifibrotic effects. 
Genetic linkage and whole genome association studies have also been reported, 
significantly associated loci being compared with the results of gene expression profiling 
studies (Shih et al., 2012).  Two such genes, MAFB and PRKX (protein kinase X-linked), 
were highlighted by both studies. PRKX contains a SNP that shows a positive association 
with Dupuytren’s disease (Li X. et al., 2011). The expression of MAFB in Dupuytren’s 
disease has been investigated by Lee et al (2006) who noted its complete absence in 
adjacent control fascia.  MafB was found to be of particular interest because of its 
prominent role in tissue development and cellular (myofibroblast) differentiation, and a 
significant co-location in some cells with alpha-smooth muscle actin (Lee et al., 2006). 
As with the puzzling array of genetic influence in the pathogenesis of Dupuytren’s disease, 
the combined effects of aging, associated changes in immune response, hormones and 
metabolism, together with the effects of co-morbidities such as diabetes mellitus, provides 
a wide range of environmental factors to influence the clinical outcome. Such a ‘pot 
pourri’ of active ingredients with possible influence on the development of a highly 
recognizable immuno-histo-chemical pathology would suggest, however, that the 
molecular pathway, once established, is little affected by environmental factors. 
Nevertheless, the environmental factors may play a very significant role in the 
establishment of the disease and therefore confound genetic studies aimed at identifying 
causative mutations or polymorphisms. 
 
3.4.6 Limitations of this study 
GWAS studies require large populations of both affected and non-affected individuals to 
be effective in isolation. The power of the Busselton study in relation to the current 
investigation is limited by the small number of identified affecteds – this does not 
represent a large enough population with Dupuytren’s disease for GWAS. It was, 
however, useful to provide a database for associations in the population study with 
possible areas of interest in common with mutations derived from the whole exome study.  
The DNA obtained from the Busselton 2006 population study encompassing a broad 
investigation of five thousand essentially unrelated adults became available for specific 
genetic analysis. Forty-eight adults were positively identified through the detailed 
questionnaire as having undergone surgery for Dupuytren’s disease, the clinical diagnosis 
thereby confirmed.  
GWAS on this cohort were considered inadequate for statistical analysis or for comparison 
with results of previous studies, eg Dolmans et al, 2011. The Busselton results, however, 
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produced a list of mutations with an OR >1.0, and with locations identified to a number 
of chromosomes of interest. Our current study has found it useful to focus on these regions 
to determine associations with genes from the WES of family members as reported in 
Chapter Two. Other than small study size making the approach underpowered the other 
significant limitation of this approach is the inability to identify potential functional 
changes that can be further interrogated. Had there been direct overlap in genes identified 
in the WES study (Chapter 2) it may have been feasible to progress further investigation 
on a common candidate using functional and genetic approaches. However, in this study, 
whilst a number of genes with relevant functions were identified as being close to 
polymorphisms with a positive association with DD, there was no insight into whether 
there were expression of functional changes in the identified genes. This limits the ability 
to further interrogate these findings and is a significant limitation of all GWAS studies. 
 
Taking into account the broad spectrum of clinical involvement as exhibited by the 
variable Dupuytren’s phenotype found among members of one family, and the 
unpredictable nature of disease progression, the variable severity of this disease may be 
due to different levels of interaction between genetic and environmental factors possibly 
triggering different levels of activated/suppressed signaling pathways. 
 
 
 
  
CHAPTER 4 
Aim 3 
Investigation of the presence of rare mutations in unrelated individuals with the severe 
Dupuytren’s phenotype by whole exome sequencing, and comparison with findings from 
affected family members and the community-based study of unrelated affecteds. 
 
4.1 Introduction 
The previous work using Whole Exome Sequencing of family members and data from a 
population based study has identified a small number of candidate genes that may 
contribute to Dupuytren’s pathology. To further investigate the significance of specific 
genes to molecular changes underlying the development of this pathology and verify the 
range of genes involved it was considered advantageous to investigate the presence of rare 
mutations in unrelated individuals with severe Dupuytren’s disease using whole exome 
sequencing.    
 
Whole exome sequencing is considered appropriate for the investigation of inherited 
pathology within a family cohort. The initial sequencing of DNA from family members 
with Dupuytren’s disease (Ch 2) has identified mutations common to all individuals; this 
number was reduced by a selection process which identified candidates which responded 
to a functional data base and excluded a large number of variants found in the general 
population and considered unlikely to be specific to this disease.  
To further investigate the potential validity of these candidates the DNA from two 
unrelated individuals with a Dupuytren’s phenotype considered to be aggressive and 
severe has been included in this study for whole exome sequencing. Mutations identified 
from their DNA are then matched against those selected from the family affecteds to 
further reduce the possible mutations considered to have functional involvement in 
Dupuytren’s disease. 
 
4.2 Methods 
The protocols for collection of DNA and Whole Exome Sequencing were followed as 
described in Chapter 2.  
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Two unrelated individuals with aggressive disease were also included in this study. They 
were assessed as severe cases by the following criteria; early age of onset (40 or younger), 
bilateral hand involvement with Dupuytren’s disease, known positive family history of 
Dupuytren’s disease, and progressive active palmar fibromatosis with digital contractures. 
Analysis of data followed the protocols as described in Chapter 2.  
 
4.2.1 Pathway analysis 
For pathway analysis a combined gene list of all candidate genes of interest identified 
from all three studies (family WES, Busselton GWAS and Severe brother study) was 
generated. The gene list was uploaded to the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) version 6.8 (1) to look for gene ontology groups and 
pathways enriched from the genes of interest. For the gene ontology analysis, the groups 
“GOTERM_BP_DIRECT”, “GOTERM_CC_DIRECT” and “GOTERM_MF_DIRECT” 
were selected and run with an EASE score of 0.2, a modification of the Fisher’s Exact test 
to measure whether independent groups can fall into one of two mutually exclusive 
categories. Resulting data was exported to excel. Pathway data was analysed in a similar 
way, using an EASE score of 0.2 and the “KEGG_PATHWAY” option. Resulting data 
was exported to excel, and images of pathways with genes involved also exported (Huang 
et al, 2008). 
 
 
 
4.3 Results 
The following table lists the genetic mutations identified as occurring in both the severe 
Dupuytren cases as heterozygous mutations. 
 
 
 
 
 
Table 4.1:Non-synonymous polymorphisms identified in two related individuals with severe Dupuyren’s disease 
List of mutations identified in both individuals and that had a predicted deleterious effect on the protein as medium or 
high for impact severity. These were identified and screened as described (methods section), with the focus on 
mutations likely to have a higher level of effect given that these patients were early onset and exhibited a severe 
progressive disease pattern. 
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To assess this larger list of mutations for possible functional significance and correlation 
to the genes identified in previous chapters (2 and 3) gene set enrichment analysis (GSEA) 
was conducted using the online DAVID tool (Huang et al, 2008). GSEA provides a 
method to identify pathways and processes that are significantly over-represented in entity 
lists. This can be help identify important themes in large datasets and overcomes some of 
the limitations of low powered studies that cannot identify significant changes at the 
individual gene/polymorphism level. 
Pathways identified as being significantly over-represented in the combined studies in 
this thesis using gene ontology categorization include cell morphogenesis and protein 
turnover pathways (Table 4.2). Other pathways that were potentially enriched (but do 
not reach statistical significance) include cell proliferation, migration and apoptosis 
(Table 4.2). 
 
Table 4.2: Gene ontology enrichment analysis. Processes including heart morphogenesis and cellular proliferation 
and apoptosis are enriched in the candidate gene lists identified in this study (table shows pathway identified by, % of 
pathway genes enriched in the target gene list, P value and genes from the target gene list identified in each pathway. 
Term ID Term Name % PValue Genes 
GO:0003007 heart morphogenesis 2.362205 0.016698 ZMIZ1, TBX1, LEFTY1 
GO:0061157 mRNA destabilization 1.574803 0.036595 METTL3, MEX3D 
GO:0051865 protein autoubiquitination 2.362205 0.038386 
LRSAM1, TRIM17, 
TRIM21 
GO:0001934 
positive regulation of protein 
phosphorylation 3.149606 0.04433 
MAVS, NTRK3, TBX1, 
STK4 
GO:0006623 protein targeting to vacuole 1.574803 0.048496 VPS13C, PIK3R4 
GO:0000902 cell morphogenesis 2.362205 0.056509 
NOX4, SHROOM3, 
STK4 
GO:0000096 
sulfur amino acid metabolic 
process  0.066076 BHMT, GCLM 
GO:0030855 epithelial cell differentiation 2.362205 0.069931 TOLLIP, TBX1, ACTL8 
GO:0030212 
hyaluronan metabolic 
process 1.574803 0.071864 ITIH4, ITIH3 
GO:0006750 
glutathione biosynthetic 
process 1.574803 0.094663 GGT6, GCLM 
GO:0008285 
negative regulation of cell 
proliferation 4.724409 0.099541 
NOX4, ENPP7, 
CYP27B1, BCHE, 
IGFBP7, STK4 
 Using KEGG pathway analysis significantly enriched pathways were for Huntington’s 
disease and Focal adhesions (Table 4.3).  
 
Table 4.3:KEGG pathway analysis. Pathways enriched in the gene lists identified in this study include Focal 
adhesions and Huntingtons disease (table shows pathway identified by KEGG, % of pathway genes enriched in the 
target gene list, P value and genes from the target gene list identified in each pathway. 
 
Category Term Name % PValue Genes 
KEGG_PATHWAY Huntington's disease 3.15 0.030359 
TGM2, CREB5, 
DNAH1, DCTN1 
KEGG_PATHWAY Focal adhesion 3.15 0.048892 
ITGA6, TLN2, 
COL6A5, MYLK 
KEGG_PATHWAY Mucin type O-Glycan biosynthesis 1.575 0.172553 
GALNTL6, 
GALNT16 
 
The genes enriched in the focal adhesion pathway are highlighted in Figure 4.1 in the 
context of the whole pathway used for this annotation (Fig. 4.1). Genes identified in this 
pathway originate from the family WES study (COL6A5), the Busselton study (TLN2) 
and the WES of the severe affected individuals (ITGA6). This indicates that this 
pathway has a gene that may be disrupted in each of the studies and points to a potential 
common pathway that may in part underpin Dupuytren’s disease. 
GO:0030335 
positive regulation of cell 
migration 3.149606 0.106131 
NTRK3, ITGA6, 
SEMA3G, MYLK 
GO:0043065 
positive regulation of 
apoptotic process 3.937008 0.115882 
NOX4, NTRK3, ITGA6, 
TGM2, STK4 
GO:0048844 artery morphogenesis 1.574803 0.122382 ZMIZ1, TBX1 
GO:0002576 platelet degranulation 2.362205 0.133774 LEFTY2, ITIH4, ITIH3 
GO:0034341 
response to interferon-
gamma 1.574803 0.138609 CYP27B1, TRIM21 
GO:0006936 muscle contraction 2.362205 0.142209 DYSF, TPM1, MYLK 
GO:0007569 cell aging 1.574803 0.143952 NOX4, ZMIZ1 
GO:0048589 developmental growth 1.574803 0.143952 ZMIZ1, ASPM 
GO:0003341 cilium movement 1.574803 0.154539 CFAP53, DNAH1 
GO:0007155 cell adhesion 4.724409 0.155893 
CLCA2, ITGA6, TLN2, 
COL6A5, IGFBP7, 
CD226 
GO:0007389 pattern specification process 1.574803 0.159783 SHROOM3, TBX1 
GO:0016925 protein sumoylation 2.362205 0.163759 BLM, RANBP2, SENP5 
GO:0044344 
cellular response to fibroblast 
growth factor stimulus 1.574803 0.170176 TBX1, GCLM 
GO:0043588 skin development 1.574803 0.190582 ITGA6, SLITRK5 
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Figure 4.1:Focal Adhesion Pathway genes implicated in DD The focal adhesion pathway is over-represented in the 
combined lists of target genes identified in the genetic studies in this thesis. Figure shows focal adhesion pathway 
with genes identified in the genetic studies highlighted with red star symbol. 
4.4 Discussion   
The reason for investigating the genetic profile of unrelated individuals with severe/ 
aggressive Dupuytren’s phenotype was the potential to identify mutations 
(polymorphisms) in genes previously identified but that would be rare mutations (since 
severe Dupuytren’s disease is very uncommon in comparison to late onset disease) and 
that these mutations would have a more deleterious effect on protein function, thereby 
leading to the earlier onset and excessive nature of the disease in those with the severe 
phenotype.  When restricting the list of non-synonymous mutations identified in both 
individuals with severe disease to those with a predicted moderate/severe effect on protein 
function, heterozygous and in less than 0.1% of the population, a total of 93 
polymorphisms were identified. This is a large number of potential candidates and is an 
interesting observation given that these are rare non-synonymous mutations identified to 
be in common in two unrelated individuals. Despite this large number of potential 
candidate genes, as in the previous studies (Chapters 2 and 3), no overlap in candidate 
genes was observed in the list of genes obtained from the unrelated individual analysis 
when compared to the previous studies.   
 
4.4.1 Identification of potential target genes 
Given the extensive list of potential candidate genes identified it is unsurprising that there 
are genes of interest with functions that can be hypothesized to be relevant to DD 
contained within. There are many different matrix associated proteins with functions that 
are likely or have been well described to be important in fibrosis, including Integrins 
(ITGA6 and ITGA7), members of the ADAMTS family (a disintegrin and 
metalloproteinase with thrombospondin motifs family), Collagen genes (including 
COL5A1) and cadherin related proteins (CDHR4). All of these genes have key roles in 
maintaining and regulating the ECM: cell interactions and are therefore plausible 
candidates for involvement in DD given the known pathology of the disease. Similar to 
the previous studies presented in Chapters 2 and 3, genes with known roles in immune 
responses (for example ITIH4 and LAIR1) and genes important in the regulation of 
vascularization (for example ANGPTL4) are also candidate genes that can be 
hypothesized to be involved in DD pathology. Interestingly, ANGPTL4 is associated with 
Type II Diabetes, which is itself associated with DD, and ANGPTL4 plays an important 
role in vascularization and a response to hypoxia, which has previously been hypothesized 
to be the underlying cause of DD. However, despite the presence of genes with relevant 
functions and polymorphisms predicted to be deleterious, these findings are weakened by 
the presence of many other rare polymorphisms in both individuals that were predicted to 
be moderately or severely deleterious but occur in genes with roles most likely unrelated 
to the disease. This makes interpretation of these findings alone difficult, as would be 
expected when using WES on only two unrelated individuals. However, in the context of 
the previous studies and combining the findings from these studies it becomes apparent 
that there are specific pathways that may be common across the individuals that have been 
investigated and this may provide insight into the pathogenesis of DD. 
 
4.4.2 Pathway analysis of combined genes of interest 
Given the lack of direct overlap between these studies a pathway analysis was used to 
identify any pathways that may be in common, albeit affected by polymorphisms in 
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  89 
  
  
different genes that may underpin DD. Using this pathway analysis focal adhesions 
appeared to be significantly enriched. Interestingly this pathway contained genes 
identified in each of the three independent studies, suggesting that in each study, family, 
Busselton and severe unrelated individuals, there was a gene identified of interest that is 
involved in focal adhesions and the signals generated by them.Focal adhesions are a type 
of adhesive contact between cells and the extracellular matrix. They are critical structures 
that facilitate communication between cells and the environment and can be involved in 
biomechanical sensing and signaling (for example changes in matrix physical properties 
such as stiffness) as well as biochemical signaling (mediating biological signals for 
cell:cell and cell:matrix communication). Focal adhesions are critical to many different 
processes and the intracellular signaling stimulated by focal adhesions is mediated by 
Focal adhesion kinase (FAK). FAK has been demonstrated to be critical to TGFb signaling 
and in the induction of profibrotic genes in response to TGFb signaling (Liu et al 2007). 
More recently targeting FAK has been demonstrated to ameliorate fibrosis in a number of 
animal models of fibrosis, suggesting this signaling pathway is critical (Lagares, 2013; 
Kinoshita K, 2013). Therefore strong evidence exists for the importance of focal adhesions 
in fibrosis and this suggests the identification of this pathway potentially being affected 
by polymorphisms identified in the studies presented here is important to follow-up with 
further work to characterize the impact of these polymorphisms and the role they may play 
in DD. 
4.4.3 Summary 
To identify gene mutations common to unrelated individuals exhibiting evidence of 
Dupuytren’s phenotype with a clinical picture suggestive of severe or aggressive disease, 
the DNA from two males with early-onset, progressive, bilateral palmar fibromatosis and 
a positive family history of Dupuytren’s disease was submitted to analysis by whole 
exome sequencing. No genes directly linked to the previous studies were identified. 
However, the importance of focal adhesions has been implicated by pathway analysis and 
this warrants further investigation. In addition, other polymorphisms with clear likely 
relevance to DD warrant further investigation from those identified in individuals with a 
severe disease phenotype. Further sequencing from other unrelated individuals with 
severe disease may facilitate identifying the likely causative mutations. 
CHAPTER 5 
 
Aim 4 To investigate the functional consequences of the putative mutations identified in 
Aims 1-3 on fibroblast phenotype and pathobiology with relation to Dupuytren’s disease. 
 
5.1 Introduction 
The aim of this work is to identify functional mutations in genes that contribute to the 
pathology of Dupuytren’s disease using genetic methods. However, whilst the genetic 
studies may facilitate identification of mutations that are important it is essential that the 
impact of these mutations is also tested in appropriate models. Currently there is no animal 
model for Dupuytren’s disease and therefore in-vitro models are required to investigate 
the impact of mutations on Dupuytren cells. In this study fibroblasts have been isolated 
from two patients with Dupuytren’s disease. The cells were isolated from the affected site 
(test sample) and an additional tissue sample was taken from the wrist (unaffected control 
fibroblasts). A scar-in-a-jar assay was used to investigate collagen I production by both 
disease (cord) fibroblasts and control fibroblasts to determine if there were significant 
differences in collagen production in vitro using this assay. If significant differences 
between disease and control cells can be detected this assay would potentially be suitable 
for investigating the effect of identified mutations on fibroblast activity. 
 
5.2 Methods 
 
5.2.2. Scar-in-a-jar model 
The functional assays were carried out using a published protocol known as “Scar-in-a-
Jar” with some modifications (Chen et al. 2009). This method involved culturing 
fibroblasts, collagen immunostaining, microscopic imaging and semi-automated analysis 
of collagen quantitation and orientation. 
 
5.2.2.1. Cell culture and isolation 
Tissue samples were collected from consenting participants in Falcon tubes containing 
Dulbecco’s Modified Eagle Media (DMEM) with 10% foetal bovine serum (FBS) and 
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500UI/ml penicillin and 500µg/ml streptomycin (5% pen/strep) (Life Technologies, USA) 
and processed within four hours. Fibroblasts were isolated from fresh tissue by a slightly 
modified explant method. (Keira et al. 2004, Tucci-Viegas et al. 2010).  
The samples were washed with PBS containing 100UI/ml penicillin and 100µg/ml 
streptomycin (1% pen/strep) (four times, 30 seconds each). Samples were then placed in 
sterile petri dishes containing DMEM and subcutaneous tissue trimmed using a scalpel 
and forceps. The tissue was cut into small fragments (5-10 mm2) and excess media on the 
fragments was removed by blotting on a petri dish lid. About 10-12 fragments were 
transferred to each petri dish which was marked with perpendicular lines made by a scalpel 
to facilitate fragment attachment to the dish with the dermis side placed down. The dish 
was left semi-open in the fume hood for 30 minutes at room temperature for the fragments 
to adhere to the surface. Six ml of DMEM with 10% FBS and 1% pen/strep was added 
gently to the dish and then incubated at 37oC in 5% CO2. The media was changed every 
two days and any floating fragments were plated in a new dish. Outgrowths of fibroblasts 
were noticed after 7-14 days. When the cells reached 80% confluence the media and tissue 
fragments were discarded. The cells were washed with phosphate buffered saline (PBS) 
and trypsinized with 0.05% trypsin with EDTA (Life Technologies, USA), then seeded 
into a T75 flask.  
 
KF and NF were seeded at a density of 5 x 104 cells/well in 4-chamber slides (Lab-Tek, 
ThermoFisher Scientific, USA) in 1 ml of Dulbecco’s modified eagle medium nutrient 
mixture F-12 (DMEM/F12, Life Technologies, USA) with 10% fetal bovine serum (FBS, 
Invitro Technologies, Noble Park North, Australia) and 1% penicillin/streptomycin (P/S, 
GIBCO®, Life Technologies, USA). After 14 hours incubation at 37oC in 5% CO2, KF 
and NF media was removed and replaced by 1 ml of Un-stim media (3 wells) or Stim 
media (3 wells). The Un-stim media contained DMEM with 1% P/S, 0.5% FBS and 1% 
of 100 mM L- ascorbic acid 2-phosphate (Sigma Aldrich, USA). The Stim media was Un-
stim media containing 37.5 mg/ml Ficoll PM70 (Fc70, GE Healthcare, UK), 25 mg/ml 
Ficoll PM400 (Fc 400, GE Healthcare, UK) and 5 ng/ml-1 transforming growth factor 
beta 1 (TGFβ1, R & D Systems, USA). The cultured cells were maintained at 37oC in 5% 
CO2 for 6 days before starting the staining.  
 5.2.2.2. Immunohistochemistry 
The immunohistochemistry for COL1A was carried out using the “Scar-in-a-Jar” protocol 
(Chen et al. 2009) with some modifications. After 6 days of culturing with Un-stim or 
Stim media the media was removed and the cultured fibroblasts washed once with 
FluoroBrite DMEM (GIBCO®, Life Technologies, Grand Island, New York, USA). 
Samples were then blocked with 3% bovine serum albumin (BSA, Sigma-Aldrich, St. 
Louis, Missouri, USA) in FluoroBrite DMEM for 30 minutes at room temperature. The 
blocking solution was removed and primary antibody (10AB, monoclonal mouse anti-
human collagen type I, Santa Cruz Biotechnology, Dallas, Texas, USA ) diluted (1:1000) 
in 3% BSA was added to the cells and incubated at 37oC in 5% CO2 for 90 minutes 
followed by one wash with FluoroBrite DMEM.  A solution of 4% paraformaldehyde 
(Sigma Aldrich, USA) in PBS was added to the cells and incubated for 10 minutes at room 
temperature followed by two washes with FluoroBrite DMEM. The secondary antibody 
(AlexaFluor 488 goat anti-mouse IgG, Life Technologies, Eugene, Oregon, USA) diluted 
(1:500) in FluoroBrite DMEM was added to the cells and then incubated for 30 minutes 
at 37oC in 5% CO2 followed by one wash with FluoroBrite DMEM. The nucleolus was 
stained for 10 minutes at room temperature with Hoechst (Life Technologies, USA) 
diluted (1:1000) in FluoroBrite DMEM. The Hoechst solution was then removed and 
followed by two washes with PBS. PBS was removed and coverslips were mounted on 
the slides using Prolong Gold antifade mounting solution (Life technologies, USA). Nail 
polish was added to fix the coverslips before imaging.  
 
5.2.2.3 Assessment of collagen quantitation  
The imaging of the experiments was undertaken using a Nikon inverted research 
microscope (TE 300) and the Nikon NIS-Elements software (Nikon, Japan). The entire 
well was tiled and scanned using a 4X objective, B2-A (488nm), DAPI (358nm) filter 
blocks; and using the same imaging alignments for both the collagen and nuclear staining 
(Figure 5.2). The exposure time was set at 300ms for the Hoechst stain and 1s for the 
collagen staining (488nm excitation).  
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For each well, several rectangular ROIs (3-6) were used to cover as much of the stained 
area of the well as possible. The same dimensions and number of rectangles were applied 
for both the collagen staining and its corresponding nuclear staining. Each rectangular 
area had a binary threshold applied to mark either the cell nuclei or the collagen fibers. 
Once the threshold was adjusted to minimize background and ensure an accurate read, the 
object count and binary area covered were measured (Figure 5.2). The obtained data was 
exported to Excel. For each well, the sum of binary areas obtained from measuring the 
collagen staining was divided by sum of its corresponding object count obtained from 
measuring the nuclear staining to give an estimation of the amount of collagen secreted 
per cell. The collagen per cell obtained from each ROI was used in the statistical analysis.  
 
5.2.2.4 Flourescence resonance energy transfer assay of procollagen 
 A Fluorescence Resonance Energy Transfer (FRET) assay was carried out to measure 
procollagen concentration in cell media using the human pro-collagen type 1, 10000 tests 
kit from Cisbio (Cat. No. 63ADK014PEH), according to the manufacturer’s instructions. 
16μL of cell media was added to a single well of the 384 well plate, (Greiner 384 low 
volume white plates, high base 4-25ul working volume, Cat. No. 784075, Interpath), to 
which 2μL of the anti-human procollagen cryptate antibody and 2μL of the anti-human 
procollagen d2 antibody was also added. A standard curve was made up the same way, 
with the procollagen standards ranging from 0.78-100ng/ml, as well as a negative control 
and a cryptate control. Each sample was run in triplicate. The plate was incubated at room 
temperature overnight, then read on a BMG Clariostar microplate reader. Microplate 
reader settings were as follows: excitation filter – 330nm, emission filters – 620nm and 
665nm, integration delay (lag time) 60μs, integration time 400μs, number of flashes – 200, 
gain – 2400. For each well, the ratio of the 665nm/620nm was calculated, then the mean 
ratio calculated using the triplicate wells for each sample and standard. The delta F% was 
then calculated by using the following equation – (ratio of the standard or sample – ratio 
negative control)/ratio negative control x 100. The delta F% values for the standard curve 
were then plotted, the equation of the line worked out and the procollagen concentration 
of each sample calculated.    
 
5.2.2.5. Statistical analysis 
For each experimental condition, the individual data from each ROI for both the 
quantitation and the coherency of collagen were used for statistical comparison. Statistical 
significance between all experimental conditions was calculated using the Kruskal-Wallis 
(non-parametric) test with corrections for multiple testing. Statistical significance between 
two selected groups was calculated using the Mann-Whitney U-test (nonparametric). P-
value < 0.05 was considered significant. All statistical analysis was carried out using 
Prism software v.6.0 (GraphPad, La Jolla, CA). 
 
5.3 Results 
The scar-in-a-jar model was tested using normal skin fibroblasts from an unrelated 
individual and collagen production compared to fibroblasts isolated from a keloid scar. 
Keloid scar fibroblasts were used as an example of fibroblasts from a progressive fibrotic 
disease and were therefore expected to be similar in characteristics to Dupuytren disease 
fibroblasts. In unstimulated conditions normal skin fibroblasts produced minimal collagen 
I (Fig 5.3.1a, e), and this was significantly increased when stimulated with TGfb (Fig 
5.3.1b, e). In contrast keloid derived fibroblasts produced significantly higher levels of 
collagen I without TGFb stimulation (Fig 5.3c, e, f) when compared to normal skin 
fibroblasts and also significantly increased collagen I expression in response to TGFb 
stimulation (Fig 5.3d, e, f). This was true in two different keloid patient samples tested 
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and suggests collagen I production in-vitro is increased in keloid fibrosis derived 
fibroblasts when compared to normal skin derived fibroblasts. 
 
The same experiment was then conducted using cells derived from two patients with 
Dupuytren’s disease and cells 
isolated from the cord and 
wrist (disease and control 
respectively). Similar to the 
observations with normal skin 
fibroblasts neither control nor 
disease fibroblasts produced 
significant levels of collagen I 
in normal culture conditions 
(Figure 5.3.2 a-d). However in 
response to TGFb stimulation 
all cells increased collagen I 
production significantly (Fig 
5.3.2 e-h).  
Collagen I immnostaining and nuclei staining (green and blue respectively) for normal skin unstimulated (NF1-
US) and stimulated (NF1-S) fibroblasts (a, b) and keloid unstimulated (KF-US) and stimulated (KF-S) 
fibroblasts (c, d). Keloid fibroblasts produce significantly more collagen in vitro without stimulation when 
compared to normal skin fibroblasts (e, f) 
Figure 5.3.1: Collagen quantitation in scar-in-a-jar model with normal skin and 
keloid scar fibroblasts 
  
To further investigate collagen production in Dupuytren fibroblasts cell supernatants were 
isolated and collagen I synthesis production analysed using a FRET assay (Fig. 5.3.3). 
Low levels of Collagen I were produced in unstimulated disease (a) and control (b) cells. 
Significantly increased collagen I production was observed after TGFb stimulation (Fig. 
5.3.3a, b). However, no difference was observed between control and disease fibroblasts 
in either unstimulated or stimulated conditions. 
  
 
 
 
Collagen I immunostaining (green) and nuclei 
(blue) using unstimulated conditions and 
fibroblasts from patient 1 cord (a) and wrist (b) 
and from patient 2 cord (c) and wrist (d). No 
significant collagen I production was detected. 
After stimulation with TGFb, cells from patient 1 
cord (e) and wrist (f) and patient 2 cord (g) and 
wrist (h) all expressed significantly higher levels 
of collagen I. No differences between control and 
disease derived fibroblasts, or between these cells 
and those from unrelated normal skin samples, 
was observed. 
 
Figure 5.3.2:Collagen quantitation in 
scar-in-a-jar model with fibroblasts 
from the wrist (control) and dupuytren 
cord (test). 
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Collagen I production measured as 
concentration of propeptide in cell media. The 
production of collagen I is shown over 6 days 
in control (a) and disease (b) fibroblasts in 
unstimulated (red) and stimulated (+TGFb) 
media (blue). Increased collagen I synthesis is 
observed after stimulation with TGFb in both 
control and disease fibroblasts. No significant 
difference between control and disease 
fibroblasts was observed. 
 
 
 
 
 
 
 
 
 
Discussion 
This investigation was to determine whether the scar-in-a-jar assay and the measurement 
of collagen I production could be used as a tool to interrogate the effect of identified 
functional mutations on fibroblast function. Since DD, as with other fibrotic disease, is 
characterized by excess collagen production it was hypothesized that disease cells would 
produce higher levels of collagen than control normal skin fibroblasts. Interestingly, 
whilst keloid fibroblasts produced excess collagen when compared to normal skin cells, 
this was not the case with DD fibroblasts. In this assay DD fibroblasts appeared to produce 
very little Collagen I without TGFb stimulation, as seen with control and unrelated normal 
skin fibroblasts. The response to TGFb was also similar between disease and control cells 
Figure 5.3.3:FRET assay of collagen I 
production by control and Dupuytren 
fibroblasts 
with no significant difference in the elevated levels of collagen I produced. The levels of 
collagen production were confirmed using two different assays which correlated closely, 
suggesting the methodology of detection was valid and that there is no difference in the 
DD fibroblast collagen production in vitro when compared to normal skin controls. The 
use of alternative methodology or models may have shown a difference in Collagen 
production not observed in this study. However, the scar-in-a-jar protocol allows 
examination of fibrillar collagen deposition, rather than pro-collagen production (FRET 
or Western blot assays) or in the case of qPCR transcription of the gene of interest. 
Examining the end product of collagen synthesis (fibrillar collagen) is important since 
collagen deposition can be regulated both intracellularly as well as extracellularly. 
Therefore by examining the end product of synthesis this protocol allows measurement of 
the collagen production most similar to that observed in vivo in the case of fibrotic disease.  
This is potentially a better system than inferring increases in ECM collagen deposition by 
looking at earlier stages of synthesis that may or may not result in increased deposition. 
However, this method is limited, as are many others, by the investigation of de novo 
matrix production rather than mimicking the production of collagen by cells already 
within a matrix, as occurs in vivo. 
The findings in this study are potentially interesting and important for a number of 
reasons. First, it is clear that other skin fibrotic disease such as keloid does lead to 
increased production of collagen I using this assay. This suggests that the fibroblast 
activity in keloid disease is at least in part autonomous, as without additional stimulation 
keloid fibroblasts produce elevated levels of collagen I in vitro. In contrast the DD cells 
do not produce elevated levels of collagen I in vitro, whilst it is clear that excess collagen 
deposition occurs in vivo in this disease. Therefore, it is likely that the excess collagen 
deposition observed in vivo may be caused by factors other than changes in the fibroblast. 
Factors affecting fibroblast collagen production are numerous and have been investigated 
in many fibrotic conditions. One key factor is the matrix interaction with the cell itself. It 
has been shown that fibroblasts will respond to changes in matrix stiffness, and part of 
this response includes changes in collagen production (Wells RG, 2013). Surprisingly, it 
appears that increased matrix stiffness stimulates increased collagen production, creating 
a positive feedback loop that may in part underpin progressive fibrosis (Duscher D et al, 
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2015; Rittie L, 2015). The assays conducted in this chapter were done in-vitro with no 
control over the stiffness of the matrix the cells encountered. Therefore, it may be that in 
DD it is matrix changes that are important in fibroblast activity and this explains the 
absence of differences between control and DD cells observed here. However, tissue 
culture plastic, the surface on which cells are grown in this study and many others, has a 
stiffness much higher than any encountered in physiological matrices. Thus is may be that 
this very high level of stiffness has an impact on fibroblast phenotype. It would be 
interesting to pursue further studies of fibroblast activity using matrices designed to reflect 
physiological and increased stiffness conditions to determine if this impacts on DD 
fibroblasts. 
Alternatively, it may be that other cell signals are important in driving fibroblast activity 
in DD. There are many inflammatory signals that are known to be profibrotic, but also 
recent evidence that epithelial cells, particularly in response to damage, can secrete 
profibrotic signals which in the context of normal wound repair promote restoration of the 
tissue barrier. However, these signals can be activated for prolonged periods or 
inappropriately and lead to excessive scarring or progressive fibrosis in this context. 
It is also possible that hypoxia may play a role, and this can also be replicated in vitro to 
determine whether this is an important factor in DD pathology and fibroblast activity. 
Evidence exists that hypoxia may be important in fibrosis and in DD, both from the 
epidemiological link to Diabetes and reduced peripheral circulation but also through more 
mechanistic studies.  
These issues highlight the complexity of fibrosis and replicating a useful model of fibrotic 
disease in vitro. Clearly, in vivo, the Dupuytren disease fibroblasts produce excess 
collagen I and this is sustained. However, this could not be replicated in the in vitro model 
here using a culture of only fibroblasts and as outlined above this may be due to many 
different factors that could be important. The use of more complex co-culture models (to 
mimic the effects of inflammatory or epithelial cells), as well as physical constraints using 
gels to mimic stiffness or stretch effects on the cells are likely to be important to more 
closely mimic the in vivo situation and provide a significant difference in collagen 
production between disease and unaffected cells. The fact that this does not appear to be 
the case in keloid disease cells, which produce excess collagen I in vitro with no additional 
stimulus, is a very interesting finding. It suggests that whilst closely related in the fibrotic 
pathology, keloid and Dupuytren’s disease are very distinct in their molecular pathology, 
and this is worthy of further investigation. 
 
5.4.1 Summary 
This study suggests that the scar-in-a-jar assay for collagen production is not suitable for 
assessing phenotypic variability between DD and normal skin fibroblasts. Therefore, other 
in-vitro assays are required for investigation of functional mutations that may contribute 
to DD. The findings also suggest that fibroblast activity in DD may be aberrant in-vivo 
due to other factors. These could be physical changes to the matrix or other signaling 
molecules produced from other cell types. Further investigation into the effects of matrix 
stiffness on DD cell activity may clarify whether DD cells are sensitive to matrix changes 
or whether other signaling is important. In addition, more complex in-vitro models 
involving the use of multiple cell types may be warranted to understand the potential role 
of cell signaling in promoting the progressive fibrosis observed in DD.  
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CHAPTER  SIX 
 
6.1 Summary 
To place this study in context I will quote from an early investigation by Terek et al (1995) 
from Boston which sought to demonstrate that the gene for the B chain of platelet-derived 
growth factor is expressed in Dupuytren’s contracture. “The presence of platelet-derived 
growth factor B and its receptor in patients who have Dupuytren (sic) contracture suggests 
that platelet-derived growth factor B (PDGFB) acting through an autocrine and paracrine 
loop may account for the proliferation, contracture and abnormal biochemistry of 
fibroblasts in Dupuytren contracture. Future treatment strategies may be directed at 
reversing or counteracting this abnormality in gene expression“(Terek et al,1995).  
In overtwenty years since that published article a large volume of research into 
Dupuytren’s disease has focused on trying to identify the molecular pathology 
underpinning Dupuytren’s disease. Whilst the fibromatous changes that occur during 
Dupuytren’s disease are well characterized in contrast, despite the many studies, a clear 
understanding of the molecular basis of the disease remains elusive. In 1994 Boerwinkle 
and Chan wrote “It is a developing paradigm in medical practice and research that both 
genetic and environmental factors are key contributors to disease aetiology and 
pathophysiology (Boerwinkle and Chan, 1994). Whilst it is undoubtedly the case that 
environmental factors play a role in the development of the disease, there is also strong 
evidence for a genetic basis for the disease. It is clear that a large proportion of individuals 
with the Dupuytren’s phenotype demonstrate a familial trait which is most commonly 
found to be inherited in an autosomal dominant fashion with variable expression and 
incomplete penetrance, based upon epidemiological studies. The difference in 
Dupuytren’s disease incidence observed between different ethnicities also highlights an 
important role for genetics. 
In this thesis a combination of different genetic approaches has been used to investigate 
the molecular pathology of Dupuytren’s disease in Western Australia. The justification 
for further genetic investigation is the continued need to identify candidate genes 
underlying Dupuytren’s pathology. By using a previously untried combination of genetic 
studies (Whole Exome Sequencing Analysis for family samples from those with mild and 
severe disease and a Genome Wide Association Study of a WA population) the aim was 
to use the combined datasets to identify genes that play functional roles in the development 
of Dupuytren’s disease.   
The genetic defects underlying inherited traits have traditionally been investigated 
using linkage analysis which involved the use of microsatellite markers located 
throughout the genome as the basis for identifying regions inherited only in affected 
individuals within a family, ‘linking’ the causative defect to the regions identified. In 
the case of Dupuytren’s disease, a previous linkage study performed in a Swedish 
population was indicative of an important region being located on Chromosome 16. 
(Hu et al., 2005). However, traditional linkage studies such as this have been limited 
by low resolution and an inability to progress to identification of specific genes of 
interest.  
More recent approaches using single nucleotide polymorphisms (SNPs) as markers 
throughout the genome to identify regions of interest have provided much higher 
resolution and greater ability to identify gene mutations involved in disease (Stranger, 
Stahl, & Raj, 2011). However, significant challenges in identifying causative 
mutations and functional data still remained (Edwards, Beesley, French, & Dunning, 
2013).  
 
 
Functional mutations can be identified in specific genes by using whole exome 
sequencing (WES) in studies of inherited diseases. This approach involves 
sequencing the part of the genome encoding for proteins to identify non-synonymous 
mutations that are likely to affect protein function and therefore underl ie disease.  It 
has the significant advantage over GWAS methodology in actually identifying 
functional mutations in specific genes that can be further characterized (Bao et al., 
2014; Rabbani et al., 2014) 
The DNA of four related individuals with a clinical diagnosis of Dupuytren’s disease was 
submitted for Whole Exome Sequencing (WES). Results obtained from sequencing these 
four family members with Dupuytren’s phenotype provided a set of potentially important 
mutations. However, no mutations of interest appeared to segregate with members of the 
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family that also had Dupuytren’s disease. No genes identified were similar to previous 
studies using a GWAS approach or linkage approach (Hu et al, 2005; Holman et al, 2011). 
Similarly, there was no overlap between the candidate genes identified and genes close to 
SNPs that were potentially associated with Dupuytren’s disease in the Busselton study 
(Chapter 3). Finally, related individuals with a severe disease phenotype were also 
investigated using WES. It was hypothesized that these individuals may have different 
mutations within the same genes as those with a mild phenotype that led to the more 
aggressive disease. However no overlap between the genes identified in this study and the 
previous studies was observed. Pathway analysis to identify potentially common pathways 
affected by genes across the studies did not clearly identify important pathways that were 
likely to be common across the individuals investigated. However, groups of genes with 
related functions within each study suggests the pathology may not be directly related to 
fibroblast activity but rather indirect influence on activity through other body systems. 
 
6.2 Identification of causative mutations in Dupuytren’s disease 
The current study has provided an analysis of DNA from three separate cohorts. The 
limitations of these methods have been discussed in individual chapters and are dominated 
by the inability to obtain sufficient statistical power for the GWAS study, limited numbers 
within each family study and the complexity of incomplete penetrance of the disease.   
Further whole exome sequencing of DNA obtained from two unrelated affecteds with a 
clinical history and phenotype suggesting severe or aggressive disease identified a set of 
different mutations, none of which demonstrated overlap with results of previous analyses. 
They did bring to light two groups of genes, however, that might suggest alternative 
pathways that could be significant in triggering this histology. 
There are a number of key reasons that may contribute to the lack of commonality across 
the genetic studies and to the continued difficulty in identifying key mutations in this 
study. These include; 
1. For the family and related individual WES studies the incomplete penetrance of 
Dupuytren’s disease may impact on the findings. Whilst only family members that were 
clinically assessed as positive cases of Dupuytren’s disease were initially sequenced to 
identify potential causative mutations, confirmation required sequencing of identified 
mutations in both positive and negative DD family members to demonstrate segregation 
of the mutation with the disease. However, it is possible that either due to age of some 
individuals sequenced that they were yet to express the Dupuytren phenotype and were 
incorrectly assigned as negative for DD. In addition, there may be members of the family 
that were negative for DD but did inherit a contributing mutation and did not develop the 
disease due to other environmental/genetic factors. There is also the possibility, since 
Dupuytren’s disease is a common disease, that an individual family member with the 
disease may have a sporadic cause rather than the same genetic mutation prevalent in the 
family. There are also limitations of WES in the coverage and calling of each exon for 
every gene. This can result in specific genes with lower coverage for individual exons and 
lead to false negatives whereby mutations are not identified. 
One key issue with using WES approach is that it will only identify mutations within the 
coding region of genes. This is a small fraction of the genome and recent studies of the 
human genome have clearly demonstrated the importance of entire regions of DNA that 
are non-coding and that influence expression of genes. Therefore, it is possible that the 
mutations do not lie within the exome at all and will be missed by this approach. 
 
2. For the Busselton study which involved a GWAS type approach to a small population in 
Western Australia the key limitation is the lack of power of the approach given the small 
population and very small number of positive cases of Dupuytren’s disease. In addition, 
those identified as positive for Dupuytren’s disease were not assessed by plastic surgeons 
but were self-identified through questionnaires. Whilst this is unlikely to affect those that 
reported having an operation for DD, those that report having banding within the palm 
may be subject to misidentification. Another possible issue is the relatedness of the people 
within the study. This can lead to the identification of SNPS not associated with the 
disease but rather because a number of the affected individuals are more closely related 
than the control population. Finally, given the wide range in age, it is possible that many 
of the ‘unaffected’ in the Busselton study were not at the age where Dupuytren’s disease 
would be apparent. This would result in the control samples containing a number of those 
that are likely to develop DD in the future. However, this has a much smaller effect on the 
study than the likely relatedness of the positive individuals. 
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Two distinct approaches have largely been used to investigate DD. These are genetic 
approaches, as described here and including GWAS studies, or alternatively a 
transcriptome/proteomic approach interrogating disease-state cells for key changes when 
compared to control cells. These proteomic/transcriptomic studies have focused on 
isolating and investigating fibroblast activity as these are known to be the cells that drive 
collagen production in fibrosis, a hallmark of DD and other fibrotic diseases. However, 
the two key advantages of the genetic approach are that this does not assume a specific 
cell type is the driver of disease, and this may be important given our increasing 
understanding that fibrosis may be initiated and sustained by immune and other responses 
which drive fibroblast collagen production rather than by aberrant fibroblast activity itself. 
In addition, the advantage of the genetic approach is that the use of disease cells can inhibit 
the ability to find changes that drive disease when there are multiple other changes that 
are caused by the disease progression or are simply bystander changes associated with the 
pathology. Again the genetic approach avoids the difficulty of sorting disease-associated 
changes from disease-driving changes. 
 
At this point in this study functional mutations have not been linked to the pathology of 
Dupuytren’s disease. This may be due to limitations in the study or alternatively indicate 
that rather than functional changes there are regulatory elements that drive DD pathology. 
These include specific elements controlling gene expression and epigenetic changes. The 
possible impact of these changes and methodology to investigate their involvement in DD 
is discussed below. 
 
6.3 Identification of functional elements beyond the parameters of Whole Exome 
Sequencing – the ENCODE database. 
There are many well defined elements within the human genome that influence the 
expression of genes within the exome, and these have been investigated over many years, 
with the discovery of Locus Control Regions (LCRs) and enhancer elements in DNA long 
before the human genome sequence was completed. These types of regulatory elements 
will not be identified using the WES approach described in this thesis. Since 2003 it has 
been possible to identify and characterize these functional elements in much more detail 
in the human genome sequence and this work has been undertaken as part of a consortium 
pursuing the ENCODE project (ENCyclopedia Of Dna Elements), which reported 
preliminary results in 2007 and updated work in 2014 (Birney et al, 2007; Kellis et al, 
2014). The findings of the ENCODE project demonstrate large numbers of conserved and 
non-conserved elements through evolution that have significant impact on gene 
expression. In addition, recent studies have increasingly focused on the roles of long non-
coding RNA elements in regulating gene expression. This increasing awareness and 
knowledge of the diversity of regulation of gene expression adds significantly to the 
complexity of interrogating disease-causing mutations, particularly in diseases such as DD 
where there are likely to be many factors that contribute to the disease. As with our 
understanding of epigenetic regulation, this area is developing very rapidly and may lead 
to novel insights into DD and other diseases as the information becomes better understood 
and interpreted.  
 
6.5 Epigenetic influences in control of gene expression.  
In relation to fibroblast activity and collagen production there are many stages that 
contribute to the regulation of collagen levels in the extracellular matrix, from post-
transcriptional processing through to secretion, cross-linking and stability as well as 
degradation. The control of gene expression is also a critical mechanism for normal cell 
function. Epigenetic changes, that is changes to the DNA that are not sequence changes 
but structural (commonly methylation status changes or histone changes in DNA 
packaging) have been shown to be involved in several complex diseases including cancer 
and in normal development and have been investigated in fibrotic and neural disorders. 
Epigenetic changes result in increased and decreased expression of genes and are now 
well described as being important in disease. From epigenetic studies several genes, 
including Rasal1 in renal fibrosis (Bechtel et al, 2010; RASAL1 encoding an inhibitor of 
the Ras oncoprotein), Fli1 in scleroderma (Wang et al, 2006) and Thy1 in pulmonary 
fibrosis (Saunders et al, 2008) have been demonstrated to be hypermethylated and to 
induce fibroblast proliferation and the production of collagen in fibrotic disease. 
Therefore, it is feasible that there are epigenetic changes in DD that are important in the 
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disease progression. However, to date no studies have clearly demonstrated a role for 
epigenetic changes in the molecular pathology of DD. It is also possible that the epigenetic 
changes described in fibrotic conditions arise as a result of cellular changes rather than 
drive cellular change. Therefore, it will be important to characterize and understand 
whether epigenetic changes and regulation play a role in DD. 
 
6.6 Whole Genome Sequencing (WGS)     
Kellis et al, (2014) have reviewed the strengths and limitations of biochemical, 
evolutionary and genetic approaches for defining functional DNA segments and have 
concluded that the elucidation of genome function will require a combination of all three 
approaches (Kellis et al, 2014).  The extensive GWAS study by Dolmans et al (2011), 
published in the New England Journal of Medicine, implicated the Wnt signalling 
pathway in the process of fibromatosis (as did Ojwang et al, 2010, and Shih et al, 2012), 
but with the limitation of identifying a region of the genome but not the actual mutations 
involved or the molecular changes involved in the disease progression. WGS does provide 
an opportunity to interrogate the entire genome and any sequence changes that may 
contribute to disease. However, because of the increasingly large sets of data that require 
increasing numbers of patients to be interrogated, and often a lack of knowledge of the 
function of many non-coding elements in the DNA, it will not necessarily provide an 
opportunity to identify DD related mutations and their effects. This is in addition to the 
possibility that epigenetic factors play a role and the influence of environmental factors 
that may diminish the contribution of genetics to the disease phenotype. To date no WGS 
approach to DD has been attempted. This may change as decreasing costs and increasing 
speed of the approach, as well as better data analysis tools will make it more feasible for 
the investigation of the genetics of disease. 
 
6.7 The identification of molecular changes in DD using disease derived cells. 
As mentioned above, the alternative approach to genetics that has been used to try to 
identify important molecular changes in DD is cell isolation from diseased tissue and 
either transcriptomic or proteomic profiling of these cells. A comparison of gene 
expression in Dupuytren’s tissue against normal tissue has been reported by Forrester et 
al (2014), also by Zhang et al (2008) and others (reviewed in Bayat, 2012). The latter 
demonstrated a dominant increase in TGF2 expression in Dupuytren’s cord tissue and 
suggested that this gene expression profile could prove useful in developing a specific 
gene therapy for this pathology. Shih et al (2009) also used a comparative analysis of 
Dupuytren’s fibroblasts with tissue biopsies in disease-specific phenotypes for the 
purpose of identifying biomarkers (Shih et al, 2009).  
The study by Forrester et al (2014) analysed RNA isolated from five affected individuals, 
but identified over three hundred genes that were either up-regulated or down-regulated 
in the cultured Dupuytren’s fibroblasts. Their findings provide compelling evidence that 
the development and progression of Dupuytren’s disease is closely associated with 
significant up-regulation of a broad group of collagen genes and down-regulation of 
matrix metallo-proteinase and collagenase genes involved in extracellular matrix 
remodelling. These results are used to justify injection of Dupuytren’s with collagenase 
from Clostridium histolyticum, a non-surgical treatment that has resulted in short-term 
release of contractures in some cases while complicated by debilitating pain and 
significant deep tissue adhesions in the longer term (Rozen et al, 2012).  
Possibly the most significant genes up-regulated in the Dupuytren’s cells were two 
Fibroblast Growth Factor genes KGF9 and FGF11, a suite of keratin genes (KRT34), and 
others which are also involved in inflammatory diseases (Tumour Necrosis Factor) and 
found in synovial fluid in osteoarthritis and rheumatoid arthritis (TNFAIP6 and VCAM1). 
A number of genes identified as up-regulated were expressed in Diabetes and other 
conditions sometimes associated with Dupuytren’s and are therefore not reliable 
biomarkers of this condition.  
As with other studies of this type the major limitation in the use of diseased cells is the 
inability to separate driver and bystander changes in expression. In addition, these studies 
have focused largely on fibroblasts, which whilst they clearly are responsible for the 
increased collagen deposition observed, may not in themselves be pathogenic but rather 
responding to signals from other cell types that actually trigger and stimulate disease.  
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6.8 Possible non-fibroblast origin of Dupuytren’s  disease 
Several aspects of the familial inheritance and clinical and histological features of 
Dupuytren’s disease within a specific family strongly support an autosomal genetic 
component to the disease.  Findings in other genetic based studies have often focused on 
genes involved in the regulation of fibroblast activity, including pathological collagen 
production and lattice contraction in the extra-cellular matrix, as well as apoptosis and 
proliferation and alpha-smooth muscle actin expression.  Even with whole genome and 
linkage approaches the absence of definitive functional changes has led to the implicated 
genes often being highlighted as likely to have important functions in fibroblasts. In 
addition, those studies that have used Dupuytren tissue for transcriptome and proteomic 
approaches, in addition to many of the histology and immunochemical studies have 
focused on the fibroblast cells. This is understandable given the clear role of these cells in 
the pathology of the disease. However, whilst fibroblasts clearly play a role in the disease 
it is important to also focus on possible triggers and causes of the disease. This is feasible 
with genetic approaches that do not involve cell isolation or proteomic profiling and can 
lead to insight into processes that may underpin the changes that lead to Dupuytren 
fibrosis. 
The suggestion of a complex polygenic inheritance involving several pathways is readily 
accepted in light of the variable expressivity and degree of phenotypic progression (Hu et 
al, 2005; Gudmundsson et al, 2001). Differences may well depend upon the nature and 
timing of trigger factors, some of which remain to be identified. The effect of direct trauma 
to the hands remains uncertain, while some series depict Dupuytren’s as an occupational 
hazard and others suggest that occupation involving repeated pressure on the palms may 
have a contributory role in its aetiology. The occurrence of Dupuytren’s disease in females 
and others with no history of manual labour would argue against the significance of 
occupational trauma, while the very unequal incidence of Dupuytren’s between males and 
females (6:1) invokes a possible hormonal influence and in particular fluctuations in 
relation to ageing and menopause.   
A review of external factors and the possible significance of their role in this disease has 
reinforced the importance of certain ethnic, cultural and lifestyle factors, including 
northern European origins, on the incidence of Dupuytren’s.  Certain habits and co-
morbidities such as smoking and diabetes, which have been associated with Dupuytren’s 
in many epidemiological surveys may well provide a trigger or facilitating role in 
genetically susceptible individuals.  In this regard it would seem that a parallel may exist 
between Dupuytren’s fibromatosis and other diseases whose histochemical processes are 
initiated and controlled by neuronal activity. 
 
6.9 Neuronal activity/disruption and Dupuytren’s disease 
The possibility of neuronal involvement in Dupuytren’s disease may be implicated from 
the study findings. Rare mutations found in severe cases (Chapter 4) (eg BHMT,  
CACNA1A, PRX); and in the family study (LRSAM1 )from Chapter 2 (Tandan et al, 1990) 
are known to play important role in peripheral innervation. In particular, LRSAM1 
identified as a candidate for Dupuytren’s (Ch2) is involved in a peripheral neuropathy and 
this may be a significant factor if it has a role in DD. 
Referring to the skin as a neuroimmunoendocrine organ Roosterman et al (2006) drew 
attention to the neuronal function of the skin in numerous clinical disorders including 
wound healing. The histochemical changes involving inflammation, cellular proliferation, 
fibroblast activity and remodelling, which are characteristic of normal wound healing, also 
occur in palmar fibromatosis. Neuropeptides released from the cutaneous innervation are 
essential to neuroendocrine and neurovascular activity responsible for the cell 
proliferation (abnormal myofibroblasts), cytokine and growth factor production, and 
neovascularisation observed in progressive Dupuytren’s disease. 
The involvement of neuronal pathways in the triggering or progression of palmar 
fibromatosis is worth investigating further. Normal diagnostic histology has not identified 
abnormal nerve patterns in Dupuytren’s tissue but special stains and 
immunohistochemistry could be applied to fresh sections or to cultured fibroblasts to 
further investigate neuropeptides and growth factors produced by these cells. Specific 
cellular activity may be observed by electron microscopy and the functional response of 
myofibroblasts to a range of external stimuli may be tested in-vitro or in an animal model. 
Further investigation of the role of sensory neurons and their secretomes in triggering 
fibrosis has been suggested because of the frequent expression of cells capable of 
producing neuropeptides commonly identified in all forms of fibrotic disease. There may 
Investigating the Molecular Pathology of Dupuytren’s Disease                                    
 
 
  111 
  
  
be a genetic susceptibility to all of these conditions through mutations caused by infective, 
immune, traumatic, neuroendocrine, metabolic or other physiological challenges, but the 
subsequent pathway to progressive fibromatosis could involve a limited number of stages 
which respond to variable functional mutations.  
Secretomes such as cytokines and growth factors provide a favourable environment for 
cell growth and proliferation, and much depends upon a balance between neurotrophins 
and apoptosis. Subsequent remodelling depends on the relative activity of cell changes 
and chemical structure of the extracellular matrix. The stages of proliferation and 
remodelling are impacted by both genetic and environmental factors which accounts for 
some of the variability in presenting phenotype.  
A neuronal hypothesis could be tested by demonstration of in-vitro response of cultured 
fibroblasts to neuropeptides and other secretomes, and possibly reinforced by positive 
evidence of cell differentiation and proliferation. This work could be carried out using in 
vitro models that mimic stretch and/or matrix stiffness to more closely mimic the 
conditions of DD and provide insight into the interaction between innervation and fibrosis 
in DD.  
There is increasing evidence that the peripheral nervous system and autonomic nerves 
may play an important role in mediating normal wound healing, a histochemical process 
involving inflammation, cellular proliferation, fibroblast activity and remodelling 
(Roosterman et al, 2006).  These changes are also characteristic of the progressive 
fibromatosis of Dupuytren’s disease and their common molecular basis may be 
significant.  
The processes involved in wound healing involve a combination of neuro-endocrine and 
neurovascular activity, vital changes which are dependent upon neuropeptides released 
from the cutaneous innervation. These changes are also characteristic of the progressive 
fibromatosis of Dupuytren’s disease. The fundamental processes of healing and scar 
formation include cell migration and proliferation, inflammation, synthesis and secretion 
of cytokines and extracellular matrix proteins and remodeling. In individuals with a 
familial predisposition, some of these changes can become excessive in formation of 
keloid and hypertrophic scars. In keloids keratinocytes induce fibroblasts to secrete 
Connective Tissue Growth Factor (CTGF), a downstream mediator of the role of 
Transforming Growth Factor  (TGF) in enhancing fibrosis. Keratinocytes also directly 
increase the proliferation of underlying dermal fibroblasts while decreasing their 
production of collagen. 
In summary, innervation plays an important role in wound repair and tissue maintenance 
and has been demonstrated to be critical to repair in the skin. It is possible that innervation 
also plays a role in the pathobiology of DD and this warrants further investigation. 
 
6.10 Angiogenesis and a role for vascular changes in Dupuytren’s disease 
The pathological remodelling of connective tissue characteristic of scleroderma is 
suggestive of fundamental interactions between microvascular damage and inflammation 
linked to tissue fibrosis (Abraham and Varga, 2005). This complex autoimmune disease 
results in abnormally fibrotic scars in areas of increased tension (cf hypertrophic scars) 
with induction of Connective Tissue Growth Factor (CTGF) by Transforming Growth 
Factor  (TGF), a process that may be suppressed by Tumour Necrosis Factor alpha. The 
anti-sclerotic effect of TGF antibody was demonstrated in a mouse model with 
bleomycin-induced scleroderma (Yamamoto et al, 2005). Angiogiotensin II (ANG II) 
appears to inﬂuence tissue repair via activation of angiotensin I receptor (AT1R) in 
ﬁbroblasts, leading to collagen remodelling, collagen gel contraction, and upregulation of 
collagen-binding integrins in-vitro (Watson et al, 1998). Platelet-derived growth factor 
(PDGF) also plays an essential role in embryo development and is critical for tissue repair. 
Overactivity of PDGF has been linked to tumour progression of glioblastoma and 
sarcomas and has also been implicated in atherosclerosis and several fibrotic conditions, 
including pulmonary fibrosis, renal fibrosis, hepatic cirrhosis, and myelofibrosis (Heldin 
et al, 1999, 2013; Bonner, 2004).  PDGFR alpha also facilitates infections by certain 
viruses (Soroceanu et al, 2008). 
In Dupuytren’s contracture both PDGF A- and B-chain were expressed by primary cell 
cultures from palmar fibromatosis, and the expression increased when the cells were 
subjected to mechanical strain (Alman et al, 1995,1996). An immunohistochemical 
analysis revealed that PDGF A- and B-chains are present in infiltrating inflammatory 
cells.  The synthesis of PDGF by inflammatory cells is often increased in response to 
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external stimuli such as exposure to low oxygen tension or stimulation by other growth 
factors and cytokines. PDGF receptors are upregulated, suggesting a role for PDGF in 
mesenchymal cell proliferation in some autoimmune diseases including rheumatoid 
arthritis and scleroderma, both conditions not normally associated with Dupuytren’s 
disease. The possibility that reduced innervation and hypoxia contribute to DD is also 
suggested by the association of Diabetes and concurrent reduction in peripheral circulation 
with the development of DD. In the studies reported here genes with roles in angiogenesis 
and vascularization were identified as being candidates of interest with functional 
mutations. These may be investigated further as this work is progressed to continue to try 
to identify functional changes involved in DD. 
 
6.11 Fibroblasts, ECM changes and Dupuytren’s disease 
Dermal fibroblasts (DF) represent the main cellular component of the dermis and are 
implicated in the homeostatic maintenance of skin extracellular matrix (ECM). They are 
metabolically active cells and their role is associated with the synthesis and secretion of 
collagens, proteoglycans, ﬁbronectin, and metalloproteases. Dermal ﬁbroblasts are 
involved in physio-pathological processes, including wound healing and ﬁbrosis (Krieg et 
al., 2007; Werner et al., 2007) and have therefore been the dominant focus of research into 
fibrotic diseases, including DD. After injury, different factors, in particular TGF 
(Desmouliere et al., 2003), promote dermal fibroblast differentiation into myoﬁbroblasts 
(DM), characterized by the expression of alpha Smooth Muscle Actin (-SMA) (Hinz, 
2007), which is therefore used as a myofibroblast differentiation marker. The dermal 
myofibroblasts are the key effector in injury/repair processes and ﬁbrosis, as they control 
ECM component deposition, tissue contraction and wound resolution (Hinz, 2007), and 
their subsequent apoptosis is essential for tissue re-epithelization (Desmouliere et al., 
2005). Whilst fibroblasts are clearly a key cell type involved in the pathology of DD, in 
this study candidate one key advantage of the genetic approaches used in this study (and 
others) is that unlike tissue based DD studies that have isolated fibroblasts from disease 
tissue to characterize the changes involved the genetic studies allow the identification of 
genes that may be important but not related to fibroblast activity. This has clearly been 
seen in this study as not only matrix genes but other pathways have been highlighted.  
Interestingly one possible hypothesis that has not been extensively explored to explain 
DD pathology is the threshold effect that is seen in mitochondrial disorders (Bayat et al, 
2004). Severe cases of fibromatosis affecting both hands and feet tend to be particularly 
common in individuals with a positive family history. Interestingly, a known familial 
condition affecting the palms and the soles (palmoplantar keratoderma) associated with 
sensorineural hearing loss is attributable to a specific mitochondrial mutation A7445G 
(Sevior et al, 1998). Mitochondrial DNAs with substantial mutations replicate more 
rapidly than normal mitochondrial DNAs, a disproportion more noticeable in some 
specific tissues (eg muscle) and considered to be related to increasing age (Weber et al, 
1997). The variation in age of onset of Dupuytren’s fibromatosis may be related to the 
rate of accumulation and percentage of accumulated mutated mitochondrial DNA in 
affected tissues. This may be an alternative explanation for changes in fibroblast activity 
unrelated to changes in the cellular DNA or gene expression but linked instead to the 
mitochondria. 
 
6.12 Infection and Immune system involvement in DD 
 
A number of degenerative neurological disorders are also known to be caused by viruses, 
and it is this intimate association with gene mutations with functional diversity that 
provides a possible driver for the immunogenetic pathway of Dupuytren’s pathology (Li 
Zhou, 2013).  
The presence of inflammatory cells, including multinucleated macrophages in healing 
wounds, scar tissue and the fibromatoses including Dupuytren’s disease, is considered an 
indication of immune response to either tissue antigens or foreign proteins including 
viruses. The significance of immunological pathways in any phase of disease where 
inflammation is apparent in response to viral infection or other stimulus is that they may 
represent a broader target in terms of prevention or treatment (Deleidi and Isacson, 2012).  
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Verjee et al (2013), in a study of freshly isolated tissue from Dupuytren’s patients, found 
that it contained significant numbers of immune cells including activated macrophages 
and released proinflammatory protein mediators (cytokines). Of the latter only TNF 
selectively converted normal fibroblasts from the palm of patients with Dupuytren’s 
disease into myofibroblasts via activation of the Wnt signaling pathway. 
 
In 1990 Bower and co-workers published data on Dupuytren’s disease in a cohort of men 
with complications of severe HIV infection. Rather surprisingly this group of men with 
an age range of 19 to 54 years showed a prevalence of 36% with Dupuytren’s disease 
(compared with an expected 4-6% in the general population, even less in this younger age 
group). The purpose of their study was to investigate further the role of free radicals, as 
proposed by Murrell et al in 1987, in the pathogenesis of Dupuytren’s disease. Superoxide 
free radicals produced as a result of ischaemia-related conversion of xanthine 
dehydrogenase to xanthine oxidase are thought to induce proliferation of fibroblasts and 
the production of type III collagen (Murrell et al, 1987).  
The rather high prevalence of Dupuytren’s among patients with HIV (Human 
Immunodeficiency Virus) infection was thus linked with disturbed metabolism of free 
radicals. Although HIV may have originated as early as 1920, the pivotal year appears to 
be 1981 when previously healthy young gay men in Los Angeles developed a rare lung 
infection called Pneumocystis carinii pneumonia (PCP), and by December of that year 
there were 270 reported cases of severe immune deficiency among gay men and injected 
drug users with 121 fatalities.  There were also reports of men in New York and California 
with unusually aggressive Kaposi’s Sarcoma. 
Although there  are an estimated 35 million individuals worldwide now living with AIDS, 
the majority of them in sub-Saharan Africa, no further reference to an association with 
Dupuytren’s disease is available. But the potentially fatal Kaposi’s sarcoma, an 
aggressively malignant lymphovascular fibromatosis which is caused by Human Herpes 
Virus VIII, is most commonly found now in men with AIDS.  
 
 
 
 6.13 Future studies 
The current study has included identification of thirty-one candidate genes from whole 
exome sequencing of DNA in four related family affecteds (Chapter 2; Table 2.4). These 
mutations were selectively screened against SNP databases and further restricted to twelve 
non- synonymous heterozygous mutations, of which two were in regions of positive 
linkage.  Sanger sequencing of PCR fragments was focused on 3 candidate genes to 
determine whether these mutations segregated within the family in members with 
Dupuytren’s disease. GORASP1 and EXOG genes were both selected due to their 
identification in a region of positive linkage from initial analysis. In addition, COL6A5 
was also selected for sequencing due to the fundamental link between collagen deposition 
and fibrotic disease. Initial sequencing showed that no mutation segregated with the 
disease in additional family members. Further investigation of the other non-synonymous 
mutations identified in four (affected) family members (Table 2.5) could possibly identify 
significant segregation with Dupuytren’s. 
    
Whole exome sequencing from a limited number of family affecteds has possibly 
restricted the number of identifiable potential candidate genes for further investigation. 
Ideally the cohort could be expanded to include Dupuytren’s phenotype in other 
generations, as well as non-affecteds, which might provide evidence to reinforce the 
current findings.  
The problem remains with the large number of possible candidates that have been 
excluded by the selection process, all of them identified in DNA from family members 
with Dupuytren’s and a number that were found to occur in all family members.  
As expected, the WES has identified only those genes with a functional role, sequencing 
the part of the genome encoding for proteins to identify non-synonymous mutations that 
are likely to affect protein function rather than those affecting expression levels. Further 
sequencing of additional variants found in all family members to identify mutations that 
segregate with Dupuytren’s disease would be useful. Whole Genome sequencing has been 
mentioned previously as a possible approach while acknowledging the financial 
limitations and an anticipated burden of genetic information. 
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A further study of severe cases would be justified and more significant results could be 
obtained from an expanded cohort with aggressive Dupuytren’s disease, including related 
individuals with this condition. While different genes may be involved in severe cases 
their variance might be related to environmental or epigenetic factors and some gene 
overlap with those currently identified could still occur.    
Comparison with other fibrotic diseases at a molecular level has already provided some 
understanding of the processes involved and it is reasonable to maintain a belief in the 
common pathways hypothesis while understanding that not only the characteristic tissue 
structures but also trigger mechanisms will account for phenotypic variations. 
The eventual challenge of fibroblast activity and function in relation to chemical and 
neuronal responses will rest with laboratory tests in vitro, including epigenetic regulation 
of gene expression in relation to fibroblast activity. 
Our ultimate goal must be to determine the molecular mechanisms that control the 
pathogenesis of Dupuytren’s disease with the aim of prevention and/or treatment by 
molecular control.  For the functional annotation of genetic elements in a familial 
condition such as Dupuytren’s CRISPR would be ideal for identifying and targeting 
specific genetic mutations eg those candidate genes identified by exome sequencing 
(Chapters 2/4) and/or mutations identified in previous studies and presumed to be involved 
in the pathogenesis of Dupuytren’s disease. It would be useful to correct or modifiy these 
genes and observe changes in the cell phenotype and function in-vitro. This would provide 
strong evidence for a causative link between the mutations and the clinical disease state. 
The application of CRISPR in genome-wide studies would also enable large-scale 
screening for therapeutic targets and other phenotypes and will facilitate the generation of 
engineered animal models that would benefit pharmacological studies and the 
understanding and treatment of the human condition.  
 
6.14 Summary 
Possibly for the first time an integrated approach has been taken to determine a genetic 
basis for Dupuytren’s disease. The combination of a familial cohort subjected to Whole 
Exome Sequencing (WES), a larger cohort of affecteds from a community population 
survey whose DNA was sequenced by Genome Wide Association (GWAS), and a very 
limited number of unrelated individuals with evidence of a severe phenotype (WES), has 
not previously been reported. Although a number of candidate genes were identified as 
non-synonymous for Dupuytren’s in each cohort there was no overlap between these three 
groups. The hypothesis has not been proven. However, further studies of those mutations 
involving the application of specific biomarkers to Dupuytren’s fibroblasts in-vitro could 
determine specific cellular response and validate the ability of certain genes to regulate 
apoptosis, proliferation, myofibroblast differentiation, collagen and alpha smooth muscle 
actin expression and fibroblast-populated collagen lattice contraction. 
Comparisons with results from other similar studies including Dupuytren’s tissue DNA 
sequencing have also failed to identify positive overlap. The author agrees with previous 
researchers in concluding that the underlying cause of Dupuytren’s fibromatosis is a 
complex system of polygenic pathways facilitated or triggered by a variety of 
environmental factors. It remains possible, however, that further studies of neuronal 
pathways and their influence on aetiology and pathogenesis of fibromatosis could displace 
current theory regarding cell differentiation and proliferation in Dupuytren’s disease.   
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